---
document_datetime: 2023-09-21 19:45:25
document_pages: 64
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/trydonis-h-c-4702-epar-assessment-report-variation_en.pdf
document_name: trydonis-h-c-4702-epar-assessment-report-variation_en.pdf
version: success
processing_time: 69.9636882
conversion_datetime: 2025-12-23 02:39:06.096598
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

28 February 2019 EMA/137008/2019

## Assessment report

Procedure No. EMEA/H/C/WS1554

Medicinal products authorised through the centralised procedure

| Invented name:   | International non- proprietary name/Common name:                            | Product-specific application number   |
|------------------|-----------------------------------------------------------------------------|---------------------------------------|
| Riarify          | beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium | EMEA/H/C/004836/WS1554/0002           |
| Trydonis         | beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium | EMEA/H/C/004702/WS1554/0002           |

Worksharing applicant (WSA): Chiesi Farmaceutici S.p.A.

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure...............................................5                                 |                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation .................................................................................................5  |                                                                                                          |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................6                                                |
| 2. Scientific discussion                                                                                                   | ................................................................................6                        |
| 2.1. Introduction........................................................................................................6 |                                                                                                          |
| 2.2. Non-clinical aspects                                                                                                  | .............................................................................................7           |
| 2.2.1. Ecotoxicity/environmental risk assessment...........................................................7               |                                                                                                          |
| 2.2.2. Discussion on non-clinical aspects.......................................................................7          |                                                                                                          |
| 2.2.3. Conclusion on the non-clinical aspects                                                                              | .................................................................8                                       |
| 2.3. Clinical aspects                                                                                                      | ...................................................................................................8     |
| 2.3.1. Introduction.....................................................................................................8  |                                                                                                          |
| 2.3.2. Discussion and conclusion on clinical pharmacology...............................................9                  |                                                                                                          |
| 2.4. Clinical efficacy                                                                                                     | ...................................................................................................9     |
| 2.4.1. Introduction.....................................................................................................9  |                                                                                                          |
| 2.4.2. Main study TRIPLE                                                                                                   | 8........................................................................................10              |
| 2.4.3. Discussion on clinical efficacy                                                                                     | ...........................................................................35                            |
| 2.4.4. Conclusions on the clinical efficacy                                                                                | ....................................................................41                                   |
| 2.5. Clinical safety....................................................................................................42 |                                                                                                          |
| 2.5.1. Discussion on clinical safety..............................................................................54       |                                                                                                          |
| 2.5.2. Conclusions on clinical safety............................................................................56        |                                                                                                          |
| 2.5.3. PSUR cycle.....................................................................................................56   |                                                                                                          |
| 2.6. Risk management plan                                                                                                  | .......................................................................................56                |
| 2.7. Update of the Product information........................................................................58           |                                                                                                          |
| 2.7.1. User consultation                                                                                                   | ............................................................................................58           |
| 3. Benefit-Risk Balance..............................................................................58                    |                                                                                                          |
| 3.1. Therapeutic Context...........................................................................................58      |                                                                                                          |
| 3.1.1. Disease or condition                                                                                                | ........................................................................................58               |
| 3.1.2. Available therapies and unmet medical need.......................................................58                 |                                                                                                          |
| 3.1.3. Main clinical studies.........................................................................................59    |                                                                                                          |
| 3.2. Favourable effects                                                                                                    | .............................................................................................59          |
| 3.3. Uncertainties and limitations about favourable effects.............................................59                 |                                                                                                          |
| 3.4. Unfavourable effects                                                                                                  | ..........................................................................................60             |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | .........................................60                                                              |
| 3.6. Effects Table                                                                                                         | .....................................................................................................61  |
| 3.7. Benefit-risk assessment and discussion.................................................................61             |                                                                                                          |
| 3.7.1. Importance of favourable and unfavourable effects..............................................61                   |                                                                                                          |
| 3.7.2. Balance of benefits and risks                                                                                       | ............................................................................62                           |
| 3.7.3. Additional considerations on the benefit-risk balance                                                               | ...........................................62                                                            |
| 3.8. Conclusions                                                                                                           | ......................................................................................................62 |
| 4. Recommendations                                                                                                         | .................................................................................62                      |
| 5. EPAR changes........................................................................................63                  |                                                                                                          |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

* This is a general list of abbreviations. Not all abbreviations are used in this Assessment report.

ADR

Adverse drug reaction

AE

Adverse event

ANCOVA

Analysis of covariance

ANOVA

Analysis of variance

BDI

Baseline dyspnoea index

BDP

Beclometasone dipropionate

BfArM

Bundesinstitut für Arzneimittel und Medizinprodukte

bid

Twice daily

BMI

Body mass index

BP

Blood pressure

bpm

Beats per minute

CAT

COPD assessment test

CHMP

Committee for Medicinal Products for Human Use

CI

Confidence interval

COPD

Chronic obstructive pulmonary disease

CRF

Case report form

CS

Clinically significant

CSR

Clinical study report

DBP

Diastolic blood pressure

DD

Delivered dose

DDI

Drug-drug interaction

DPI

Dry powder inhaler

ECG

Electrocardiogram

eCRF

Electronic case report form

EMA

European Medicines Agency

E-RS

Exacerbations of chronic pulmonary disease tool-respiratory symptoms

EU

European Union

FDC

Fixed dose combination

FEV1

Forced expiratory volume in 1 second

FF

Formoterol fumarate

FPM

Fine particle mass

FVC

Forced vital capacity

GB

Glycopyrronium bromide

GCP

Good Clinical Practice

GOLD

Global Initiative for Chronic Obstructive Lung Disease

γGT

Gamma-glutamyltransferase

HFA

Hydroxyfluoroalkane

HR

Heart rate

IC

Inspiratory capacity

ICH

International Conference on Harmonisation

ICS

Inhaled corticosteroid

IND

Indacaterol

IRS

Interactive response system

ITT

Intent-to-treat

i.v.

Intravenous

LABA

Long-acting β 2-agonist

<div style=\"page-break-after: always\"></div>

| LAMA   | Long-acting muscarinic antagonist       |
|--------|-----------------------------------------|
| LOCF   | Last observation carried forward        |
| MAA    | Marketing authorisation application     |
| MACE   | Major adverse cardiovascular event      |
| MCID   | Minimal clinically important difference |
| MD     | Metered dose                            |
| MMRM   | Mixed model for repeated measures       |
| NA     | Not applicable                          |
| NCS    | Non-clinically significant              |
| od     | Once daily                              |
| OIP    | Orally inhaled products                 |
| PD     | Pharmacodynamic                         |
| PE     | Point estimate                          |
| PK     | Pharmacokinetic                         |
| pMDI   | Pressurised metered dose inhaler        |
| PP     | Per protocol                            |
| PT     | Preferred term                          |
| QoL    | Quality of life                         |
| QTcF   | Fridericia-corrected QT interval        |
| QTcP   | Population-corrected QT interval        |
| RI     | Renal impairment                        |
| SABA   | Short-acting  2 -agonist               |
| SBP    | Systolic blood pressure                 |
| SD     | Standard deviation                      |
| SGRQ   | St George's Respiratory Questionnaire   |
| SmPC   | Summary of Product Characteristics      |
| SOC    | System organ class                      |
| SS     | Steady-state                            |
| TDI    | Transition dyspnoea index               |
| TEAE   | Treatment-emergent adverse event        |
| TQT    | Thorough QT                             |
| vs.    | Versus                                  |

<div style=\"page-break-after: always\"></div>

## 1.  Background information on the procedure

## 1.1.  Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Chiesi Farmaceutici S.p.A. submitted to the European Medicines Agency on 26 November 2018 an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication for TRYDONIS / RIARIFY to \"Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a longacting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).'

Consequently, the indication section (4.1), Undesirable effects section (4.8) and Pharmacodynamic Properties section (5.1) of the EU SmPC to add the results of two Phase III studies (TRIPLE 7 and TRIPLE 8). The Package Leaflet and the Risk Management Plan are updated in accordance.

In addition, changes as requested by PRAC in the frame of Trimbow/Trydonis/Riarify PSUR (PRAC recommendation dated 12 July 2018), following beclometasone PSUSA/00000306/201612 were introduced in section 4.4. and 4.8 of the SmPC.

The Package Leaflet and the Risk Management Plan (version 6.0) are updated in accordance.

In addition, the WSA took the opportunity to update the list of local representatives in the Package Leaflet.

The requested worksharing procedure proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision CW/0001/2015 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

## 1.2.  Steps taken for the assessment of the product

| Timetable                                 | Actual dates     |
|-------------------------------------------|------------------|
| Submission date                           | 26 November 2018 |
| Start of procedure:                       | 31 December 2018 |
| CHMP Rapporteur Assessment Report         | 25 January 2019  |
| PRAC Rapporteur Assessment Report         | 29 January 2019  |
| PRAC members comments                     | N/A              |
| Updated PRAC Rapporteur Assessment Report | N/A              |
| PRAC Outcome                              | 14 February 2019 |
| CHMP members comments                     | 18 February 2019 |
| Updated CHMP Rapporteur Assessment Report | 20 February 2019 |
| Opinion                                   | 28 February 2019 |

## 2.  Scientific discussion

## 2.1.  Introduction

Trydonis / Riarify (hereafter also referred to as CHF 5993 pMDI) is a triple combination of an inhaled corticosteroid (ICS), a long-acting beta2 agonist (LABA) and a long-acting muscarinic receptor antagonist (LAMA). The product is a fixed dose combination of beclometasone dipropionate (BDP), formoterol fumarate (FF) and glycopyrronium bromide (GB). Trydonis / Riarify is formulated as a hydroxyfluoroalkane (HFA) solution to be delivered via a pressurised metered dose inhaler (pMDI) with a nominal dose per actuation of BDP 100 mcg (87 mcg delivered dose), FF 6 mcg (5 mcg delivered dose), and GB 12.5 mcg (9 mcg delivered dose). The doses of BDP and FF are the same as used in the dual combination of BDP/FF (Foster) which has already been licensed for the treatment of COPD in all European Countries.

The European Commission (EC) granted a marketing authorisation valid throughout the European Union for Trydonis on 26 April 2018 and for Riarify on 23 April 2018.

The application for Trydonis and Riarify were informed consent application to Trimbow application.Therefore the content of the application are similar for these medicinal product and support the same scientific information as the reference product Trimbow.

The approved indication is:

'Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1)'.

The posology is two inhalations of Trydonis / Riarify 87/5/9 micrograms twice daily.

<div style=\"page-break-after: always\"></div>

The main clinical studies supporting the approval of Trydonis / Riarify were study TRIPLE 5 (TRILOGY) and study TRIPLE 6 (TRINITY), both 52-week active controlled studies in high risk COPD patients (FEV1 less than 50% predicted, symptomatic at screening despite treatment as evidenced by a COPD assessment test [CAT] score of 10 or above, and with at least one documented moderate to severe COPD exacerbation in the year prior to study participation. Study TRIPLE 5 compared Trydonis / Riarify with a fixed combination of BDP/FF (Foster 100/6 pMDI) whereas study TRIPLE 6 compared Trydonis / Riarify with tiotropium and the open triple combination of BDP/FF (Foster) + tiotropium.

The MAH is now applying for an extension of the indication as follows:

\"Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).'

The extension of indication is primarily based on data from Study TRIPLE 8 (TRIBUTE) that compared Trydonis / Riarify with a fixed combination of IND/GB (Ultibro Breezhaler) over 52 weeks in subjects with COPD using a primary endpoint of moderate-to-severe COPD exacerbation rate over 52 weeks. Additional revisions are based on data from Study TRIPLE 7 (TRISTAR) evaluating the non-inferiority of Trydonis / Riarify compared with the open triple combination of Fluticasone/Vilanterol (Relvar Ellipta) + Tiotropium over 26 weeks in subjects with COPD.

## 2.2.  Non-clinical aspects

No new Non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1.  Ecotoxicity/environmental risk assessment

The present variation to extend the indication to include 'a combination of a long-acting beta2-agonist and  a  long-acting  muscarinic  antagonist'  will  not  lead  to  a  change  of  the  initial  environmental  risk assessment.  It  is  considered  that  the  only  impact  could  be  in  terms  of  the  market  penetration  factor (FPEN) used in the calculation of the predicted environmental concentration (PEC). However, since the FPEN in the calculation of the initial PEC encompassed the entire population of COPD patients, the change is considered not to have an impact on the Fpen and the initial PEC. Therefore, the initial environmental risk assessment (ERA) is also applicable to the present variation.

However,  the  initial  ERA  has  not  been  finalised  yet  as  still  open  issues  need  to  be  addressed.  The applicant agreed at the time to submit studies on OECD 308 and OECD 305 by 31 December 2018. In order  to  finalise  the  ERA,  the  applicant  is  asked  to  provide  the  announced  study  reports  and  the respective ERA update by 30 September 2019 within the appropriate variation. This delay was justified and agreed by the CHMP.

## 2.2.2.  Discussion on non-clinical aspects

Based on the data submitted within the initial MAA considering already the entire population of COPD patients, the new/extended indication does not lead to a significant increase in environmental exposure further to the use of BDP. No new Non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

<div style=\"page-break-after: always\"></div>

## 2.2.3.  Conclusion on the non-clinical aspects

There are no updated data have been submitted in this application, which is considered acceptable by the CHMP.

## 2.3.  Clinical aspects

## 2.3.1.  Introduction

The  proposed  extension  of  indication  is  primarily  based  upon  data  from  one  pivotal  phase  IIIb  study TRIPLE 8 and the supporting, phase IIIb study TRIPLE 7.

Data  characterising  the  pharmacokinetics  of  the  three  active  components  of  Trydonis  /  Riarify,  their pharmacokinetic  interactions,  the  pharmacokinetics  in  special  populations  and  potential  drug-drug interactions  were  included  in  the  original  submission  supporting  the  first  marketing  authorisation application for Trydonis / Riarify. No new pharmacology/ pharmacokinetic data were part of the present submission, which is acceptable by the CHMP.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

An overview on the GCP compliance audits performed by the MAH is provided in Table 1 .

Table 1: List of GCP compliance audits performed by the MAH

| No.                                                      | Type                       | Site       | Dates/Duration   | Participation in TRIPLE7/8   |   Patients SCR failure/ randomised |
|----------------------------------------------------------|----------------------------|------------|------------------|------------------------------|------------------------------------|
| Quality System Maintenance Audit (covering both studies) | [not indicated]            | 19-20MAY15 | NA               | NA                           |                                  1 |
| Site Audit                                               | #040805 Hallein (Austria)  | 11-12FEB16 | N / Y            | N=7 / N=25                   |                                  2 |
| Site Audit                                               | #428817 Jekabpils (Latvia) | 20APR16    | N / Y            | N=0 / N=17                   |                                  3 |
| Site Audit                                               | #616805 Sochaczew (Poland) | 28-29JUL16 | N / Y            | N=22 /N=23                   |                                  4 |

<div style=\"page-break-after: always\"></div>

## · Tabular overview of clinical studies

Table 1: Phase IIIb studies performed by the MAH in support of the type II variation

|                                        | Study Triple 7 CCD-05993AA1-07                                                                                                                                                                     | Study Triple 8 CCD-05993AA1-08                                                                                         |
|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Study type                             | Phase IIIb                                                                                                                                                                                         | Phase IIIb                                                                                                             |
| Design                                 | Phase IIb, randomised, open-label, active-controlled, 2-arm parallel-group, multicentre, multinational                                                                                             | Phase IIb, randomised, double-blind. double-dummy, active-controlled, 2-arm parallel-group, multicentre, multinational |
| Primary objective                      | To demonstrate the non-inferiority of CHF 5993 pMDI vs. fixed combination of Fluticasone/Vilanterol + Tiotropium in terms of quality of life (change from baseline in SGRQ total score at Week 26) | To demonstrate the superiority of CHF 5993 pMDI vs. Indacaterol/GB in exacerbation rate                                |
| Study treatment and total (daily) dose | CHF 5993 pMDI, 2 puffs bid (total daily dose: 400/24/50 μg BDP/FF/GB)                                                                                                                              | CHF 5993 pMDI, 2 puffs bid (total daily dose: 400/24/50 μg BDP/FF/GB)                                                  |
| Patients                               | Severe and very severe COPD patients                                                                                                                                                               | Severe and very severe COPD patients                                                                                   |
| Number of randomised patients          | 1157                                                                                                                                                                                               | 1532                                                                                                                   |
| Comparators and total daily dose       | Fluticasone/Vilanterol 1 inhalation od + Tiotropium 1 inhaled capsule od (total daily dose: 100/25 μg Fluticasone/Vilanterol + 18 μg Tiotropium)                                                   | Indacaterol/GB 1 inhalation od (total daily dose: 85/43 μg Indacaterol/GB)                                             |
| Treatment duration                     | 26 weeks                                                                                                                                                                                           | 52 weeks                                                                                                               |

## 2.3.2.  Discussion and conclusion on clinical pharmacology

No updated data have been provided in this application. Overall, the clinical pharmacology properties of three active components of Trydonis / Riarify have been appropriately described in the previous applications. This is acceptable by the CHMP.

## 2.4.  Clinical efficacy

## 2.4.1.  Introduction

The clinical development programme of Trydonis / Riarify (hereafter also referred to as CHF 5993 pMDI) in COPD which was the basis for the original marketing authorisation issued by the European Commission in  April  2018  included three phase II (studies GLYCO 2, TRIPLE 3 and CARSAF), one phase IIb (study TRIPLE 9) and two pivotal efficacy and safety phase III clinical studies (studies TRIPLE 5 and 6).

Results of two new phase IIIb studies (TRIPLE 7 and TRIPLE 8) are now submitted by the MAH.

Support  for  the  extension  of  the  initially  authorised  indication  to  all  adult  patients  with  moderate  to severe  COPD  mainly  comes  from  the  52-week,  randomised,  double-blind,  double-dummy,  active controlled study TRIPLE 8 comparing Trydonis / Riarify with a fixed combination of a LABA (indacaterol) and  a  LAMA  (GB)  without  inhaled  corticosteroid.  The  primary  objective  of  this  study  was  to  provide evidence by testing whether triple therapy with ICS/LABA/LAMA is superior to dual bronchodilator therapy with a LABA/LAMA combination in terms of preventing moderate to severe COPD exacerbation episodes over one year.

<div style=\"page-break-after: always\"></div>

Main  objective  of  study  TRIPLE  7  was  to  demonstrate  that  Trydonis  /  Riarify  is  non-inferior  to extemporary triple therapy (fixed combination of fluticasone and vilanterol plus tiotropium) in terms of the St. George's Respiratory Questionnaire (SGRQ) total score at week 26 as a measure of quality of life.

Efficacy  outcomes  of  this  study  are  considered  supportive  evidence  and  not  contributing  relevant  new knowledge to this type II variation as a consequence of the study design which substantially differs from that of other phase III-IIIb studies, namely by the open-label treatment and the shorter total treatment duration of 26 weeks only (thereby not preventing seasonal influences on the exacerbation rate).

Therefore and in order to avoid unnecessary complexity of this assessment report, in the remainder of this section, efficacy results of study TRIPLE 7 are brief, to the point and addressing the essential aspects only.

## 2.4.2.  Main study TRIPLE 8

## Title of Study

A 52-week, double blind, double dummy, randomized, multinational, multicentre, 2-arm parallel group, active  controlled  clinical  trial  of  fixed  combination  of  beclometasone  dipropionate  plus  formoterol fumarate  plus  glycopyrronium  bromide  administered  via  pMDI  (CHF  5993)  versus  indacaterol  / glycopyrronium (Ultibro) via DPI in patients with Chronic Obstructive Pulmonary Disease (Study Number: CCD-05993AA1-08, Eudra-CT Number: EudraCT no. 2014-001704-22).

##  Study design

Individual study participation lasted for about 52 weeks and comprised the following eight (8) investigator site on-visits as presented below and in

## Figure 1:

-  Pre-screening visit (Visit 0, V0) within no more than seven days prior to screening, performed in order  to  obtain  written  informed  consent,  also  for  restrictions  to  be  observed  prior  to  the screening visit;
-  Screening visit (Visit 1, V1) to assess a patient's preliminary eligibility for inclusion into the study, followed  by  a  2-week  open-label  run-in  period  (treatment  with  IND/GB  (85/43µg/day)  and salbutamol pMDI or terbutaline DPI as rescue medication);
-  Randomisation visit (Visit 2, V2) at week 0 (W0) when a patient's final eligibility was confirmed and eligible subjects randomised in a 1:1 ratio to receive for the next 52 weeks either

CHF 5993 pMDI, 2 puffs twice daily or matching placebo (total daily nominal dose of 400/24/50µg BDP/FF/GB)

or

IND/GB  DPI,  1  capsule  once  daily  or  matching  placebo  (total  daily  nominal  dose  of  85/43µg IND/GB)

-  Subsequent visits were performed after 4 weeks (V3), 12 weeks (V4), 26 weeks (V5), 40 weeks (V6) and 52 weeks (V7) of treatment.

Throughout study participation (i.e. during the run-in and the double-blind treatment periods), patients were  requested  to  complete  on  a  daily  basis  a  validated  digital  diary  (DIARYpro)  in  order  to  record

<div style=\"page-break-after: always\"></div>

randomised medication intake, permitted rescue medication use (salbutamol pMDI or terbutaline DPI), and EXACT-PRO questionnaire data.

Figure 1: Study design and schedule of visits

<!-- image -->

## Study participants

In order to be eligible, patients had to meet the following main inclusion criteria:

-  Male or non-pregnant female, ≥40 years of age, current or former smokers, smoking history of &gt;10 pack years;
-  Diagnosis  of severe  or very  severe  airflow  limitation  as  per  GOLD  update  2014  (postbronchodilator FEV1 &lt;50% of predicted normal; post-bronchodilator FEV1/FVC ratio &lt;0.7);
-  Symptomatic at screening (CAT score ≥10);
-  Documented  history  of  at  least  one  moderate  to  severe  exacerbation  in  the  year  prior  to screening (i.e. prescription of systemic corticosteroids and/or antibiotics, COPD-triggered visit to emergency department or hospitalisation);
-  Under dual treatment (ICS/LABA, ICS/LAMA or LABA/LAMA) or LAMA monotherapy (but not triple therapy) for at least two months prior to screening.

The presence of any of the following excluded a patient from trial participation (key exclusion criteria):

-  Current clinical diagnosis of asthma or physician-judged need for an oral or inhaled corticosteroid therapy for the disorder;
-  Known respiratory disorder other than COPD which in the opinion of the investigator may interfere with the IMPs efficacy (e.g. α1-antitrypsin deficiency, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension or interstitial lung disease);
-  Patients  requiring  systemic  corticosteroids  (&gt;3  days)  or  antibiotics  (&gt;7  days)  due  to  COPD exacerbation, antibiotic treatment for lower respiratory tract infection or PDE4 inhibitor use within 4 weeks prior to screening;
-  Occurrence of a moderate to severe COPD exacerbation during the run-in period;
-  Patients requiring long term (≥12 hours daily) oxygen therapy for chronic hypoxaemia.

<div style=\"page-break-after: always\"></div>

## Treatments

For retaining the blind, a double dummy design was used. Patients randomised to receive CHF 5993 pMDI were administered IND/GB-matched placebo and vice versa as detailed in Table 3 .

Table 3: Study treatments (Study TRIPLE 8)

| Product description                                     | Dosage                                      | Form/ Route of administration   | Packaging Batch Number Manufacturing Batch/CommercialBatch   | Packaging Batch Number Manufacturing Batch/CommercialBatch   | Expiry Date         |
|---------------------------------------------------------|---------------------------------------------|---------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|---------------------|
| BDP 100 μg/FF 6 CHF 5993 pMDI μg/GB 12.5 μg (BDP/FF/GB) |                                             | pMDI                            | E122447-19                                                   | 1016493                                                      | April 2016          |
| BDP 100 μg/FF 6 CHF 5993 pMDI μg/GB 12.5 μg (BDP/FF/GB) |                                             | pMDI                            | E122447-32 E122447-33 E122447-34                             | 1027039                                                      | February 2017       |
| BDP 100 μg/FF 6 CHF 5993 pMDI μg/GB 12.5 μg (BDP/FF/GB) | per puff                                    | pMDI                            | E122447-42                                                   | 1043891                                                      | March 2018          |
| BDP 100 μg/FF 6 CHF 5993 pMDI μg/GB 12.5 μg (BDP/FF/GB) |                                             | pMDI                            | E122447-48                                                   | 1043891                                                      | March 2018          |
| CHF 5993 pMDI- matched placebo                          | Only excipients                             | pMDI                            | E122447-19                                                   | B21206                                                       | April 2016          |
| CHF 5993 pMDI- matched placebo                          | Only excipients                             | pMDI                            | E122447-20 E122447-30 E122447-31                             | 1024720                                                      | February 2017       |
| CHF 5993 pMDI- matched placebo                          | Only excipients                             | pMDI                            | E122447-42                                                   | 1024720                                                      | March 2018          |
| CHF 5993 pMDI- matched placebo                          | Only excipients                             | pMDI                            | E122447-48                                                   | 1024720                                                      | March 2018          |
| Indacaterol/GB (Ultibro?)                               | Indacaterol 85 μg/GB 43 μg per hard capsule |                                 | E122447-21                                                   | 1022765/S0031                                                | November 2015       |
| Indacaterol/GB (Ultibro?)                               | Indacaterol 85 μg/GB 43 μg per hard capsule |                                 | E122447-22                                                   | 1026829/ S0050                                               | February 2016       |
| Indacaterol/GB (Ultibro?)                               | Indacaterol 85 μg/GB 43 μg per hard capsule |                                 | E122447-28                                                   | 1031301/S0090                                                | July 2016           |
| Indacaterol/GB (Ultibro?)                               | Indacaterol 85 μg/GB 43 μg per hard capsule |                                 | E122447-29                                                   | 1031305/ S0112 1031307/ S0099                                | July 2016           |
| Indacaterol/GB (Ultibro?)                               | Indacaterol 85 μg/GB 43 μg per hard capsule |                                 | E122447-35                                                   | 1038098/S0118                                                | November 2016       |
| Indacaterol/GB (Ultibro?)                               | Indacaterol 85 μg/GB 43 μg per hard capsule |                                 | E122447-38                                                   | 1038531/ S0119                                               | November 2016       |
| Indacaterol/GB (Ultibro?)                               | Indacaterol 85 μg/GB 43 μg per hard capsule |                                 | E122447-40                                                   | 1043984/S0178                                                | April 2017          |
| Indacaterol/GB (Ultibro?)                               | Indacaterol 85 μg/GB 43 μg per hard capsule |                                 | E122447-41                                                   | 1047665/S0207                                                | June 2017           |
| Indacaterol/GB (Ultibro?)                               | Indacaterol 85 μg/GB 43 μg per hard capsule | DPI                             | E122447-47                                                   | 1053606/S0242                                                | August 2017         |
| Indacaterol/GB- matched placebo                         | Only excipients                             |                                 | E122447-21                                                   | 1021415 1021316                                              | November 2015       |
| Indacaterol/GB- matched placebo                         | Only excipients                             |                                 | E122447-22                                                   |                                                              | February2016        |
| Indacaterol/GB- matched placebo                         | Only excipients                             |                                 | E122447-28                                                   | 1021415 1021415                                              | July 2016 July 2016 |
| Indacaterol/GB- matched placebo                         | Only excipients                             |                                 | E122447-29                                                   | 1021316                                                      |                     |
| Indacaterol/GB- matched placebo                         | Only excipients                             |                                 | E122447-35                                                   |                                                              | November 2016       |
| Indacaterol/GB- matched placebo                         | Only excipients                             |                                 | E122447-38                                                   | 1021316                                                      | November 2016       |
| Indacaterol/GB- matched placebo                         | Only excipients                             |                                 | E122447-40                                                   | 1034088                                                      | April 2017          |
| Indacaterol/GB- matched placebo                         | Only excipients                             |                                 | E122447-41                                                   | 1034088                                                      | June 2017           |

Patients who were used taking previous COPD pMDI medications via a spacer were requested to use the AeroChamber Plus™ for administration of the study medication.

Salbutamol  pMDI  or  terbutaline  DPI  were  permitted  for  use  as  rescue  medication  and  prescribed  / purchased locally. The maximum doses allowed for salbutamol and terbutaline were 8 and 4 puffs per day, respectively. The Investigator had to be contacted in case the patient's need for rescue medication exceeded the maximum doses allowed for more than 2 consecutive days.

## Objectives

## Primary objective:

To demonstrate the superiority of CHF 5993 pMDI over IND/GB (Ultibro) in terms of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbation rate over 52 weeks of treatment.

<div style=\"page-break-after: always\"></div>

Secondary objectives:

-  To evaluate the effect of CHF 5993 pMDI on other lung function parameters, patient's health status and clinical outcome measures;
-  To assess the safety and the tolerability of the study treatments.

## Outcomes/endpoints

The  TRIPLE  8  study  had  a  single  primary  outcome,  i.e.  the  rate  of  moderate-to-severe  COPD exacerbations over 52 weeks of treatment.

Definition:  A  COPD  exacerbation  was  defined  as  ' A  sustained  worsening  of  the  patient's  condition (dyspnoea, cough and/or sputum production/purulence), from the stable state and beyond normal dayto-day variations, that is acute in onset and necessitates a change in regular medication in a patient with underlying  COPD  that  includes  prescriptions  of  systemic  corticosteroids  and/or  antibiotics  or  need  for hospitalisation .' Exacerbations were classified as moderate or severe as per EMA/Committee for Medicinal Products for Human Use (CHMP) guidelines definitions:

-  Moderate: exacerbations that required treatment with systemic corticosteroids and/or antibiotics;
-  Severe: exacerbations that required hospitalisation or resulted in death.

Any unscheduled visit at any healthcare institution (e.g. emergency department, pneumological division or  physician)  was  also  classified  to  be  an  exacerbation,  provided  systemic  corticosteroids  and  or antibiotics were prescribed (moderate severity); if in addition the episode required a stay of &gt;24h, it was considered as hospitalisation and therefore classified as severe.

The recognition of potential COPD exacerbations by the investigators was supported by the daily report of worsened symptoms through an electronic diary and completion of the EXACT questionnaire. According to the  clinical  study  report,  investigators  and  site  personnel  were  notified  by  electronic  means  when  the EXACT score ' changed beyond the normal day-to-day variability' .

## Sample size

The  sample  size  was  calculated  to  demonstrate  the  superiority  of  CHF  5993  pMDI  over  the  active reference  treatment  (Ultibro)  in  terms  of  the  moderate  and  severe  COPD  exacerbations  rate  over  52 weeks  of  treatment.  Based  on  a  log-normal  distribution  for  the  time  to  drop-out  (estimated  drop-out rates of 13%, 16.5%, and 20% at weeks 12, 26 and 52), an overdispersion of 0.56, and an exacerbation rate in the reference arm equal of 0.90, a total of 1534 evaluable patients (767 patients per arm) was expected to provide sufficient statistical power (85%) to detect a rate ratio of 0.80 between CHF 5993 pMDI and the reference treatment at a two-sided significance level of 0.05.

Since  each  subject  with  a  follow-up  of  non-null  duration  provided  a  contribution  to  the  analysis,  all randomised subjects were considered to be evaluable, irrespective of whether they withdrew from the study prematurely.

Moreover, approximately 20% of patients randomised were expected to suffer from very severe airflow limitation (i.e. post-bronchodilator FEV1 at screening &lt; 30% of predicted normal value).

## Randomisation

Patients were randomly assigned to treatment groups by central balanced block randomisation scheme, stratified  by  country  and  severity  of  airflow  limitation  (post-bronchodilator  FEV1  categories  &lt;30%

<div style=\"page-break-after: always\"></div>

predicted or 30% to &lt;50% predicted) in accordance with a randomisation list generated by an interactive response technology system.

## Blinding (masking)

Patients, investigators, site staff, and sponsor personnel were masked to treatment assignment for the duration  of  the  study  by  use  of  a  double  dummy  approach.  Chiesi  Global  Pharmacovigilance  staff  had their own unblinding codes to unblind patients in case of suspected unexpected serious adverse reactions (SUSARs) to be reported to the competent Regulatory Authorities and/or the EC/IRB.

## Statistical methods

## Primary Efficacy Variable

The study had a single primary endpoint, i.e. the number of moderate to severe COPD exacerbations over 52 weeks of treatment. The number of moderate and severe COPD exacerbations was analysed using a negative  binomial  model  including  treatment,  country,  number  of  COPD  exacerbations  during  the previous year (1, &gt; 1), severity of airflow limitation (i.e. post-bronchodilator FEV1 at screening &lt; 30% or ≥ 30% of the predicted normal value) and smoking status as fixed effects and log-time on study in years as an offset. The adjusted exacerbation rate in each treatment group and the adjusted rate ratio with associated 95% Wald confidence intervals (CIs) were estimated by the model.

Superiority of CHF 5993 pMDI over IND/GB was demonstrated if the upper limit of the 95% CI for the adjusted exacerbation rate ratio was &lt; 1.

## Secondary Efficacy Variables

- Time  to  first  moderate  or  severe  COPD  exacerbation  and  time  to  first  severe  COPD  exacerbation were  analysed  using  a  Cox  proportional  hazard  regression  model  including  treatment,  country, number of COPD exacerbations during the previous year (1, &gt; 1), severity of airflow limitation and smoking status as factors. A Kaplan-Meier plot was also presented;
- Number of severe COPD exacerbations and number of moderate COPD exacerbations were analysed using the same model as for the primary efficacy variable;
- Changes from baseline in pre-dose morning FEV1 and FVC as well as changes from baseline in the SGRQ  total  score  and  domain  scores,  at  each  visit  and  over  the  entire  treatment  period  were analysed  using  a  linear  MMRM  including  treatment,  country,  visit,  treatment  by  visit  interaction, number of COPD exacerbations during the previous year (1, &gt; 1), severity of airflow limitation and smoking  status  as  fixed  effects,  and  baseline  and  baseline  by  visit  interaction  as  covariates.  An unstructured covariance matrix was assumed;
- FEV1 and SGRQ responses at Week 26 and Week 52 were analysed using a logistic regression model including  treatment,  country,  number  of  COPD  exacerbations  during  the  previous  year  (1,  &gt;  1), severity  of  airflow  limitation  and  smoking  status  as  factors  and  baseline  FEV1  or  SGRQ  as  a covariate;
- Changes  from  baseline  to  each  inter-visit  period  and  over  the  entire  treatment  period  in  the percentage of days, nights and complete days (i.e. day + night) without intake of rescue medication as well as in the average day-time, night-time and overall (i.e. day-time + night-time) use of rescue medication  were  analysed  using  a  linear  MMRM  including  treatment,  country,  inter-visit  period, treatment by inter-visit period interaction, number of COPD exacerbations during the previous year, severity of airflow limitation and smoking status as fixed effects, as well as baseline and baseline by

<div style=\"page-break-after: always\"></div>

inter-visit  period  interaction  as  covariates.  An  unstructured  covariance  matrix  was  assumed  and weights proportional to their duration were assigned to inter-visit periods;

- Changes from baseline to each inter-visit period and over the entire treatment period in the average EXACT-PRO total score and domain scores were analysed using the same model as for the rescue medication use ;
- Nocturnal symptoms were collected in the EXACT-PRO domain number 13 and were analysed using the same model as for the rescue medication use;
- Change from baseline in the CAT score at the end of treatment was summarised using descriptive statistics.

## Results

## Participant flow

Figure 2: Subject disposition in study TRIPLE 8

<!-- image -->

Notes: Among the screening failures, 2 patients were reported with pre-treatment AEs leading to death (PTs: sudden cardiac death and acute myocardial infarction, respectively). Among the discontinuations, 2 other patients had AEs leading to death and were recorded as discontinued due to AEs.

<div style=\"page-break-after: always\"></div>

Figure 3: Time to discontinuation from study TRIPLE 8 (Kaplan-Meier analysis, randomised population)

<!-- image -->

SourceData:Listing16.2.1.2.2

[2)Completedpatientsarecensoredatthedateofcompletion.

[3]Ateachtimepoint,thenumberofpatientsatriskispresented.

Program Name: f\\_disc.sas

CreationDate/Time:22SEP201716:06

Extract Date: 25AUG2017

Overall,  the  vast  majority  of  patients  randomised  completed  at  least  visit  6/40  weeks  of  treatment (90.1% in group CHF 5993 pMDI and 87.5% in group IND/GB, respectively), and 87.2 and 84.4 in the CHF 5993 pMDI and IND/GB groups respectively completed ≥52 weeks of treatment.

According to a Kaplan-Meier analysis, the probability of treatment discontinuation in the two groups was comparable during the first 12 weeks of treatment whereas for the remainder of the treatment period it was somewhat lower in group CHF 5993 pMDI as compared with IND/GB.

## Recruitment

A total  of  1532  patients  were  randomised  by  17  countries  (average  screening  failure  rate  27.2%  with important  between-site  variability).  The  majority  of  countries  were  European  (N=14,  82%),  two  were South-American  (Argentina,  Chile)  and  one  Central  American  (Mexico).  The  largest  proportion  of randomised patients came from Europe (N=1343, 88%); five Eastern European countries accounted for about 70% of study population (Bulgaria 20%, Romania 14%, Poland 13%, Latvia 12% and the Czech Republic 10%).

## Conduct of the study

##  Time schedule

Clinical trial protocol

03 December 2014 (Version 1)

(There  was  only  one  global,  non-substantial  amendment  and  one local substantial amendment in France)

First patient first visit (FPFV)

29 May 2015

Last patient last visit (LPLV)

10 July 2017

Data review meetings

15-16 December 2016, 22-23 May 2017, and 02-04 August 2017

<div style=\"page-break-after: always\"></div>

| Date of data review report   | 24 August 2017                   |
|------------------------------|----------------------------------|
| Statistical analysis plan    | 21 August 2017 (Version 1 Final) |
| Database lock                | 24.08.2017                       |
| Final study report           | 22 November 2017 (Final 1.0)     |

## Baseline data

Independently  of  the  population  assessed  (safety,  ITT,  PP),  demographics  were  comparable  between treatment groups (Table 4). The vast majority of patients in the safety population were white (92.2%) and predominantly male (71.8%). The median age upon screening was 65 years (range: 41 to 87 years) and the median BMI 25.6 kg/m 2  (range: 13-47). About half of the patients in both groups were between 40 and 64 years old and 10% had an age of ≥75 years.

Important characteristics of the underlying COPD were well balanced between treatment groups (Table 5). Prior to study entry, the vast majority of patients (80.8%) had experienced a single exacerbation only in  the  previous  year.  More  than  85%  of  patients  in  both  groups  received  dual  therapy  consisting  of  a LABA and an ICS (about 60%) or dual bronchodilator therapy (LABA / LAMA, about 25%).

<div style=\"page-break-after: always\"></div>

Table 4: Demographic data (randomised = safety population)

|                   | CHF5993pMDI N=764   | Indacaterol/GB N=768   | Overall N=1532   |
|-------------------|---------------------|------------------------|------------------|
| Age (years)       |                     |                        |                  |
| n                 | 764                 | 768                    | 1532             |
| Mean (SD)         | 64.4 (7.7)          | 64.5 (7.7)             | 64.5 (7.7)       |
| Range (min ; max) | 42 ; 87             | 41 ; 84                | 41 ; 87          |
| Age group, n (%)  |                     |                        |                  |
| <65 years         | 389 (50.9)          | 376 (49.0)             | 765 (49.9)       |
| 65-74 years       | 294 (38.5)          | 312 (40.6)             | 606 (39.6)       |
| ≥ 75 years        | 81 (10.6)           | 80 (10.4)              | 161 (10.5)       |
| Gender, n (%)     |                     |                        |                  |
| Male              | 548 (71.7)          | 552 (71.9)             | 1100 (71.8)      |
| Female            | 216 (28.3)          | 216 (28.1)             | 432 (28.2)       |
| Race, n (%)       |                     |                        |                  |
| White             | 705 (92.3)          | 708 (92.2)             | 1413 (92.2)      |
| Other             | 51 (6.7)            | 52 (6.8)               | 103 (6.7)        |
| Missinga          | 8 (1.0)             | 8 (1.0)                | 16 (1.0)         |
| Weight (kg)b      |                     |                        |                  |
| 1n                | 764                 | 768                    | 1532             |
| Mean (SD)         | 74.5 (16.8)         | 76.8 (17.5)            | 75.7 (17.2)      |
| Range (min ; max) | 40 ; 140            | 32;138                 | 32 ; 140         |
| Height (cm)       |                     |                        |                  |
| n                 | 764                 | 768                    | 1532             |
| Mean (SD)         | 170.1 (9.1)         | 169.7 (9.2)            | 169.9 (9.2)      |
| Range (min ; max) | 141 ; 198           | 138 ; 200              | 138 ;200         |
| BMI (kg/m2)b      |                     |                        |                  |
| n                 | 764                 | 768                    | 1532             |
| Mean (SD)         | 25.7 (5.1)          | 26.6 (5.4)             | 26.1 (5.3)       |
| Range (min ; max) | 14 ; 43             | 14 ;47                 | 14 ; 47          |

BMI = Body mass index; GB = Glycopyrronium bromide; Max = Maximum; Min = Minimum; pMDI = Pressurised metered dose inhaler; SD = Standard deviation.

N = Number of patients in the Safety population; n = Number of patients with available data.

aPer local regulations in Portugal, patients? race could not be recorded.

b At baseline (i.e. V2).

<div style=\"page-break-after: always\"></div>

Table 5: COPD history (randomised = safety population)

|                                                        | CHF 5993 pMDI N=764                                    | Indacaterol/GB N=768                                   | Overall N=1532                                         |
|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
| Time since first COPD diagnosis (years)                | Time since first COPD diagnosis (years)                | Time since first COPD diagnosis (years)                | Time since first COPD diagnosis (years)                |
| n                                                      | 764                                                    | 768                                                    | 1532                                                   |
| Mean (SD)                                              | 8.16 (5.76)                                            | 7.99 (5.64)                                            | 8.08 (5.70)                                            |
| Range (min ; max)                                      | 1.1 ; 41.4                                             | 1.1 ; 40.3                                             | 1.1 ; 41.4                                             |
| COPD phenotype* (n, %)                                 | COPD phenotype* (n, %)                                 | COPD phenotype* (n, %)                                 | COPD phenotype* (n, %)                                 |
| Chronic bronchitis                                     | 434 (56.8)                                             | 421 (54.8)                                             | 855 (55.8)                                             |
| Emphysema                                              | 227 (29.7)                                             | 235 (30.6)                                             | 462 (30.2)                                             |
| Chronic bronchitis and emphysema                       | 103 (13.5)                                             | 112 (14.6)                                             | 215 (14.0)                                             |
| COPD medication at study entry, n (%)                  | COPD medication at study entry, n (%)                  | COPD medication at study entry, n (%)                  | COPD medication at study entry, n (%)                  |
| ICS/LABA                                               | 467 (61.1)                                             | 465 (60.5)                                             | 932 (60.8)                                             |
| ICS/LAMA                                               | 36 (4.7)                                               | 24 (3.1)                                               | 60 (3.9)                                               |
| LABA/LAMA                                              | 183 (24.0)                                             | 199 (25.9)                                             | 382 (24.9)                                             |
| LAMA                                                   | 77 (10.1)                                              | 80 (10.4)                                              | 157 (10.2)                                             |
| Missing                                                | 1(0.1)                                                 | 0                                                      | 1 (0.1)                                                |
| Use of spacer at screening, n (%)                      | Use of spacer at screening, n (%)                      | Use of spacer at screening, n (%)                      | Use of spacer at screening, n (%)                      |
| Yes                                                    | 123 (16.1)                                             | 133 (17.3)                                             | 256 (16.7)                                             |
| No                                                     | 641 (83.9)                                             | 635 (82.7)                                             | 1276 (83.3)                                            |
| Number of COPD exacerbations in the previous 12 months | Number of COPD exacerbations in the previous 12 months | Number of COPD exacerbations in the previous 12 months | Number of COPD exacerbations in the previous 12 months |
| n                                                      | 764                                                    | 768                                                    | 1532                                                   |
| Mean (SD)                                              | 1.2 (0.6)                                              | 1.2 (0.5)                                              | 1.2 (0.5)                                              |
| Range (min ; max)                                      | 1;6                                                    | 1;4                                                    | 1;6                                                    |
| 1, n (%)                                               | 612 (80.1)                                             | 626 (81.5)                                             | 1238 (80.8)                                            |
| 2, n (%)                                               | 124 (16.2)                                             | 112 (14.6)                                             | 236 (15.4)                                             |
| ≥3, n (%)                                              | 28 (3.7)                                               | 30 (3.9)                                               | 58 (3.8)                                               |
| Time since last documented COPD exacerbation (months)  | Time since last documented COPD exacerbation (months)  | Time since last documented COPD exacerbation (months)  | Time since last documented COPD exacerbation (months)  |
| n                                                      | 764                                                    | 768                                                    | 1532                                                   |
| Mean (SD)                                              | 5.31 (2.82)                                            | 5.45 (2.84)                                            | 5.38 (2.83)                                            |
| Range (min ; max)                                      | 0.2 ; 12.0                                             | 0.3 ; 12.0                                             | 0.2 ; 12.0                                             |
| Last documented COPD exacerbation (n, %)               | Last documented COPD exacerbation (n, %)               | Last documented COPD exacerbation (n, %)               | Last documented COPD exacerbation (n, %)               |
| Treated with systemic corticosteroids and antibiotics  | 370 (48.4)                                             | 369 (48.0)                                             | 739 (48.2)                                             |
| Treated with systemic corticosteroids only             | 105 (13.7)                                             | 140 (18.2)                                             | 245 (16.0)                                             |
| Treated with antibiotics only                          | 289 (37.8)                                             | 259 (33.7)                                             | 548 (35.8)                                             |
| Hospitalisation/ER                                     | 174 (22.8)                                             | 164 (21.4)                                             | 338 (22.1)                                             |

COPD = Chronic obstructive pulmonary disease; ER = Emergency room; GB = Glycopyrronium bromide; ICS = Inhaled corticosteroid; Max = Maximum; Min = Minimum; LABA = Long-acting β2-agonist; LAMA = Long-acting muscarinic antagonist; pMDI = Pressurised metered dose inhaler; SD = Standard deviation.

N = Number of patients in the Safety population; n = Number of patients with available data.

a Recorded COPD phenotype was based on physician judgement and knowledge of the patient

<div style=\"page-break-after: always\"></div>

## Numbers analysed

All patients randomised (N=1532) were treated (i.e. received at least one dose of IMP) and had at least one day of follow-up after the first IMP intake. Safety and ITT populations were identical and included 100% of patients; the PP population included 1479 / 1532 patients (96.5%).

Major protocol violations were thus reported in a total of 53 patients, 22 (2.9%) in group CHF5993 pMDI and 31 (4.0%) in group IND/GB. An overview is presented in Table 6.

Table  6:  Major  protocol  deviations  leading  to  exclusion  from  the  PP  population  (violated eligibility criteria not shown)

<!-- image -->

| Deviation Type Deviation                                                                                                              | CHF 5993pMDI (N=764)                                                                                                                  | Indacaterol/glycopyrronium bromide (N=768)                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Number of Patients with at Least One Major Deviation                                                                                  | 22 (2.9)                                                                                                                              | 31 (4.0)                                                                                                                              |
| NON-ADEQUATECOMPLIANCE TO THE STUDY DRUG                                                                                              | 6 (1.2)                                                                                                                               | 11 (1.4)                                                                                                                              |
| NON-ADEQUATE COMPLIANCE TO THE STUDY DRUG                                                                                             | 9 (1.2)                                                                                                                               | 11 (1.4)                                                                                                                              |
| NONPERMITTEDMEDICATION                                                                                                                | 4 (0.5)                                                                                                                               | 12 (1.6)                                                                                                                              |
|                                                                                                                                       | 2 (0.3)                                                                                                                               | 7 (0.9)                                                                                                                               |
| USE OF ICS，LABA，LAMA,SABA (OTHER THAN RESCUE)，SAMA AND COMBINATIONS FOR >30 DAYS                                                      | 0                                                                                                                                     | 4 (0.5)                                                                                                                               |
| USE OF NASALCORTICOSTEROIDS                                                                                                           | 1 (0.1)                                                                                                                               | 1 (0.1)                                                                                                                               |
|                                                                                                                                       | 1 (0.1)                                                                                                                               | 1 0.1)                                                                                                                                |
| USE OF NON-CARDIOSELECTIVE BETA-BLOCKERS                                                                                              | 0                                                                                                                                     | 1 (0.1)                                                                                                                               |
| USE OF SABA (OTHER THAN RESCUE)，SAMA，SABA+SAMA OR ICS FOR COPD EXACERBATION FOR >30 DAYS                                              | 0                                                                                                                                     | 1 (0.1)                                                                                                                               |
| SourceI Data: Listing 16.2.2.1.1                                                                                                      |                                                                                                                                       |                                                                                                                                       |
| Notes: [1]Patients can have more than one major protocol deviation. [2] Table presents number and percentage of patients (n (&)). [3] | Notes: [1]Patients can have more than one major protocol deviation. [2] Table presents number and percentage of patients (n (&)). [3] | Notes: [1]Patients can have more than one major protocol deviation. [2] Table presents number and percentage of patients (n (&)). [3] |

## Outcomes and estimation

Rate of Moderate-to-Severe COPD Exacerbations over 52 weeks of treatment (Primary Endpoint)

Over 52 weeks of treatment, less patients in group CHF 5993 pMDI experienced less moderate-to-severe exacerbations  (35.7%,  433  events)  as  compared  with  IND/GB  (37.5%,  485  events)  (ITT  population). Thus, the adjusted exacerbation rate per patient per year was lower with CHF 5993 pMDI (0.504, 95% CI [0.447, 0.569]) as compared with IND/GB (0.595 [0.530, 0.668]) (Table 6).

The resulting adjusted rate ratio was 0.848 (95% CI [0.723, 0.995]), thereby confirming a statistically significant  reduction  of  15.2%  in  the  rate  of  moderate-to-severe  COPD  exacerbations  and  thus  the superiority of CHF 5993 pMDI over IND/GB (p=0.043).

Results of the PP analysis for the primary variable evolved in the same direction though no more meeting statistical significance (adjusted rate ratio of 0.849, 95% CI [0.721, 1.000], p=0.05) (Table 7). The predefined sensitivity analyses (conducted to evaluate the impact of different methods for handling missing data  or  the  impact  of  discrepancies  in  the  severity  of  airflow  limitation  as  recorded  in  IRS  and  eCRF) showed similar trends and thereby confirmed the overall conclusions.

<div style=\"page-break-after: always\"></div>

Table 7: Rate of moderate-to-severe COPD exacerbations (ITT population)

|                                         |                                                      |                                                      | CHF5993pMDI N=764    | Indacaterol/GB N=768   |
|-----------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------|------------------------|
| Total follow up time (years)            | Total follow up time (years)                         | Total follow up time (years)                         | 717.97               | 707.36                 |
| All Moderate/ Severe COPD Exacerbations | Number (%) of Patients with Exacerbations            | Number (%) of Patients with Exacerbations            | 273 (35.7)           | 288 (37.5)             |
| All Moderate/ Severe COPD Exacerbations | NumberofExacerbations                                | NumberofExacerbations                                | 433                  | 485                    |
| All Moderate/ Severe COPD Exacerbations | Exacerbation Rate per Patient per Year               | Exacerbation Rate per Patient per Year               | 0.603                | 0.686                  |
| All Moderate/ Severe COPD Exacerbations | Adj. Exacerbation Rate per Patient per Year (95% CI) | Adj. Exacerbation Rate per Patient per Year (95% CI) | 0.504 (0.447, 0.569) | 0.595 (0.530, 0.668)   |
| All Moderate/ Severe COPD Exacerbations | CHF 5993 pMDI Vs. Indacaterol/GB                     | Adj. rate ratio (95% CI)                             | 0.848 (0.723, 0.995) | 0.848 (0.723, 0.995)   |
| All Moderate/ Severe COPD Exacerbations |                                                      | p-value                                              | 0.043                | 0.043                  |

Adj. = Adjusted; CI = Confidence interval; COPD = Chronic obstructive pulmonary disease; GB = Glycopyrronium bromide;

ITT = Intention-to-treat; pMDI = Pressurised metered dose inhaler; vs. = Versus.

N = Number of patients in the ITT population.

Table 8: Rate of moderate-to -severe COPD exacerbations (PP population)

|                                         |                                                      |                                                      | CHF 5993 pMDI N=744   | Indacaterol/GB N=739   |
|-----------------------------------------|------------------------------------------------------|------------------------------------------------------|-----------------------|------------------------|
| Total follow up time (years)            | Total follow up time (years)                         | Total follow up time (years)                         | 701.60                | 682.74                 |
| All Moderate/ Severe COPD Exacerbations | Number (%) of Patients with Exacerbations            | Number (%) of Patients with Exacerbations            | 265 (35.7)            | 271 (36.8)             |
| All Moderate/ Severe COPD Exacerbations | Number of Exacerbations                              | Number of Exacerbations                              | 412                   | 456                    |
| All Moderate/ Severe COPD Exacerbations | Exacerbation Rate per Patient per Year               | Exacerbation Rate per Patient per Year               | 0.587                 | 0.668                  |
| All Moderate/ Severe COPD Exacerbations | Adj. Exacerbation Rate per Patient per Year (95% CI) | Adj. Exacerbation Rate per Patient per Year (95% CI) | 0.486 (0.430, 0.551)  | 0.573 (0.508, 0.645)   |
| All Moderate/ Severe COPD Exacerbations | CHF 5993 pMDI VS. Indacaterol/GB                     | Adj. rate ratio (95% CI)                             | 0.849 (0.721, 1.000)  | 0.849 (0.721, 1.000)   |
| All Moderate/ Severe COPD Exacerbations |                                                      | p-value                                              | 0.050                 | 0.050                  |

Adj. = Adjusted; CI = Confidence interval; COPD = Chronic obstructive pulmonary disease; GB = Glycopyrronium bromide; pMDI = Pressurised metered dose inhaler; PP = Per-protocol; vs. = Versus.

The treatment effect was greater in patients with severe airflow limitation (30%≤FEV1&lt;50% predicted), current  smokers,  females,  patients  with  chronic  bronchitis  phenotype  COPD,  patients  who  had  only  a single documented COPD exacerbation in the year prior to enrolment, and those with a relative eosinophil count at screening of ≥2% (Figure 4).

<div style=\"page-break-after: always\"></div>

Figure 4: Forest plot for moderate-to-severe COPD exacerbation adjusted rate ratios over 52 weeks

<!-- image -->

CI = Confidence interval; COPD = Chronic obstructive pulmonary disease; FEV1 = Forced expiratory volume in the 1st second; IRT = Interactive response technology; ITT = Intention-to-treat; MI = Multiple imputation; pMDI = Pressurised metered dose inhaler; PP = Per-protocol.

N = Number of patients in the population.

Note: Bars represent 95% CI, vertical dotted line at 1 represents the limit for the demonstration of superiority.

The results  of  the  primary  efficacy  analysis  and  of  all  the  sensitivity  analyses  of  the  moderate/severe COPD exacerbation  rate,  including  the  additional  one  based  on  the  J2R  approach,  are  summarised  in Figure 5. The sensitivity analyses confirmed the results of the primary efficacy analysis with very similar estimates  of  the  exacerbation  rate  ratio  (range:  0.847  -  0.859)  despite  the  conservative  assumptions considered  in  some  scenarios  (CR  and  J2R).  Such  consistent  results  support  the  superior  efficacy  of Trydonis / Riarify compared Indacaterol/GB in the reduction of moderate/severe COPD exacerbations.

<div style=\"page-break-after: always\"></div>

Figure 5: Adjusted Moderate/Severe COPD Exacerbation Rate Ratio, TRYDONIS / RIARIFY vs. Indacaterol/GB - Study TRIPLE 8

<!-- image -->

Note: Bars represent 95% CI.

Rate of moderate exacerbation and severe exacerbation over 52 weeks (Secondary Endpoints)

Table 9: Severe COPD exacerbations - ITT population

|                                                      |                                                      | CHF 5993 pMDI N=764   | Indacaterol/GB N=768   |
|------------------------------------------------------|------------------------------------------------------|-----------------------|------------------------|
| Total follow up tine (years)                         | Total follow up tine (years)                         | 717.97                | 707.36                 |
| Severe COPD Exacerbations                            | Severe COPD Exacerbations                            |                       |                        |
| Number (%) of Patients with Exacerbations            | Number (%) of Patients with Exacerbations            | 62 (8.1)              | 69 (9.0)               |
| Number (%) of Exacerbationsa                         | Number (%) of Exacerbationsa                         | 72 (16.6)             | 91 (18.8)              |
| Exacerbation Rate per Patient per Year               | Exacerbation Rate per Patient per Year               | 0.100                 | 0.129                  |
| Adj. Exacerbation Rate per Patient per Year (95% CI) | Adj. Exacerbation Rate per Patient per Year (95% CI) | 0.074 (0.055, 0.099)  | 0.094 (0.072, 0.123)   |
| CHF 5993 pMDI vs. Indacaterol/GB                     | Adj. rate ratio (95% CI)                             | 0.787 (0.551, 1.125)  | 0.787 (0.551, 1.125)   |
| CHF 5993 pMDI vs. Indacaterol/GB                     | p-value                                              | 0.189                 | 0.189                  |
| COPDExacerbationsleadingtodeaths                     | COPDExacerbationsleadingtodeaths                     |                       |                        |
| Number (%) of Patients with Exacerbations            | Number (%) of Patients with Exacerbations            | 2 (0.3)               | 2 (0.3)                |
| Number (%) of Exacerbationsa                         | Number (%) of Exacerbationsa                         | 2 (0.5)               | 2 (0.4)                |
| Exacerbation Rate per Patient per Year               | Exacerbation Rate per Patient per Year               | 0.003                 | 0.003                  |
| COPD Exacerbations leading to hospitalisationb       | COPD Exacerbations leading to hospitalisationb       |                       |                        |
| Number (%) of Patients with Exacerbations            | Number (%) of Patients with Exacerbations            | 62 (8.1)              | 68 (8.9)               |
| Number (%) ofExacerbationsa                          | Number (%) ofExacerbationsa                          | 72 (16.6)             | 90 (18.6)              |
| Exacerbation Rate per Patient per Year               | Exacerbation Rate per Patient per Year               | 0.100                 | 0.127                  |

Adj. = Adjusted; CI = Confidence interval; COPD = Chronic obstructive pulmonary disease; GB = Glycopyrronium bromide; ITT = Intention-to-treat; pMDI = Pressurised metered dose inhaler; vs. = Versus.

N = Number of patients in the ITT population.

b Emergency room admissions with at least 24 hours of stay have been also considered as hospitalisations.

a Percentages are based on the number of moderate/severe COPD exacerbations in the relevant treatment/population.

<div style=\"page-break-after: always\"></div>

Table 10: Moderate COPD exacerbations - ITT population

|                                                      |                                                      | CHF 5993 pMDI N=764   | Indacaterol/GB N=768   |
|------------------------------------------------------|------------------------------------------------------|-----------------------|------------------------|
| Total follow up time (year's)                        | Total follow up time (year's)                        | 717.97                | 707.36                 |
| ModerateCOPDExacerbations                            | ModerateCOPDExacerbations                            |                       |                        |
| Number (%) of Patients with Exacerbations            | Number (%) of Patients with Exacerbations            | 231 (30.2)            | 237 (30.9)             |
| Number (%) of Exacerbationsa                         | Number (%) of Exacerbationsa                         | 361 (83.4)            | 394 (81.2)             |
| Exacerbation Rate per Patient per Year               | Exacerbation Rate per Patient per Year               | 0.503                 | 0.557                  |
| Adj. Exacerbation Rate per Patient per Year (95% CI) | Adj. Exacerbation Rate per Patient per Year (95% CI) | 0.408 (0.356, 0.468)  | 0.471 (0.413, 0.537)   |
| CHF 5993 pMDI vs. Indacaterol/GB                     | Adj. rate ratio (95% CI)                             | 0.866 (0.723, 1.037)  | 0.866 (0.723, 1.037)   |
| CHF 5993 pMDI vs. Indacaterol/GB                     | p-value                                              | 0.118                 | 0.118                  |

Adj. = Adjusted; CI = Confidence interval; COPD = Chronic obstructive pulmonary disease; GB = Glycopyrronium bromide;

ITT = Intention-to-treat; pMDI = Pressurised metered dose inhaler; vs. = Versus.

N = Number of patients in the ITT population.

a Percentages are based on the number of moderate/severe COPD exacerbations in the relevant treatment/population.

## Time to First Moderate-to-Severe Exacerbation (Secondary Endpoint)

Time  to  the  first  moderate-to-severe  exacerbation  was  prolonged  with  CHF  5993  pMDI,  resulting  in  a numerically  lower  probability  of  exacerbation  in  the  Cox  proportional  hazards  analysis  (hazard  ratio  of 0.901, 95% CI [0.763; 1.064], p=0.219).

## Change from Baseline in Trough FEV1 at Week 52 (Secondary Endpoint)

In  both  treatment  groups,  there  was  a  small  decline  in  pre-dose  morning  FEV1  over  the  52-week treatment period. The adjusted mean difference in trough FEV1 between treatments was consistently in favour of CHF 5993 pMDI (Figure 6 and Table 11). At week 52, the pre-dose morning FEV1 had a slightly, but  statistically  significantly  decrease  in  both  groups  with  no  significant  between  group  difference (adjusted mean changes of -0.029, 95%CI [-0.046; -0.012] in group CHF 5993 pMDI and -0.049, 95%CI [-0.066; -0.031] in group IND/GB; adjusted mean difference 0.019, 95%CI [-0.005; 0.043].

The adjusted mean change in pre-dose morning FEV1 from baseline averaged over the entire treatment period  did  not  differ  from  baseline  with  CHF  5993  pMDI  (-0.003L,  95%CI  [-0.016;  0.010],  p=0.602), while it slightly decreased under treatment with IND/GB (-0.026 L, 95%CI [-0.039; -0.013], p&lt;0.001). The  adjusted  mean  difference  between  groups  was  small,  but  statistically  significant  (0.022,  95%CI [0.004; 0.040], p=0.018).

In  the  FEV1  responder  analysis,  the  percentage  of  patients  in  whom  the  pre-dose  morning  FEV1  had increased by ≥100 mL at week 52 was numerically greater in group CHF 5993 pMDI (19%) as compared with IND/GB (16.3%), resulting in an odds ratio of 1.190 (95%CI [0.913; 1.550], p=0.198).

<div style=\"page-break-after: always\"></div>

Figure 6: Adjusted  mean  change  from  baseline  in  pre-dose  morning  FEV1  in  L  (ITT population)

<!-- image -->

CI = Confidence interval; FEV1 = Forced expiratory volume in the 1st second; ITT = Intention-to-treat; pMDI = Pressurised metered dose inhaler; R = Indacaterol/GB; T = CHF 5993 pMDI.

Note: Bars represent 95% CI and the symbol * statistically significant difference between treatments (p &lt; 0.05).

Table 11: Change from baseline in pre-dose morning FEV1 in L at week 52 and over the entire treatment period (ITT population)

|                               |                                  |                               | CHF 5993 pMDI N=764     | Indacaterol/GB N=768    |
|-------------------------------|----------------------------------|-------------------------------|-------------------------|-------------------------|
| Baseline                      | Baseline                         | n                             | 761                     | 767                     |
|                               |                                  | Mean (SD)                     | 1.122 (0.364)           | 1.130 (0.387)           |
| Week 52                       | Actual values                    | n                             | 669                     | 652                     |
| Week 52                       |                                  | Mean (SD)                     | 1.110 (0.403)           | 1.103 (0.406)           |
| Week 52                       | Change from baseline             | n                             | 668                     | 652                     |
| Week 52                       |                                  | Mean (SD)                     | -0.025 (0.244)          | -0.052 (0.224)          |
|                               |                                  | Adj. mean (95% CI)            | -0.029 (-0.046, -0.012) | -0.049 (-0.066, -0.031) |
|                               | CHF 5993 pMDI vs. Indacaterol/GB | p-value                       | <0.001                  | <0.001                  |
|                               |                                  | Adj. mean difference (95% CI) | 0.019 (-0.005, 0.043)   | 0.019 (-0.005, 0.043)   |
|                               |                                  | p-value                       | 0.116                   | 0.116                   |
| Average over treatment period | Change from baseline             | Adj. mean (95% CI)            | -0.003 (-0.016, 0.010)  | -0.026 (-0.039, -0.013) |
| Average over treatment period | CHF 5993 pMDI vS. Indacaterol/GB | p-value Adj. mean             | 0.602                   | <0.001                  |
| Average over treatment period |                                  | difference (95% CI)           | 0.022 (0.004, 0.040)    | 0.022 (0.004, 0.040)    |
| Average over treatment period |                                  | p-value                       | 0.018                   | 0.018                   |

Adj. = Adjusted; CI = Confidence interval; FEV1 = Forced expiratory volume in 1st second; GB = Glycopyrronium bromide; ITT = Intention-to-treat; pMDI = Pressurised metered dose inhaler; SD = Standard deviation; vs. = Versus.

N = Number of patients in the ITT population; n = Number of patients with available data.

<div style=\"page-break-after: always\"></div>

## Change from Baseline in SGRQ Total Score at Week 52 (Secondary Endpoint)

In both treatment groups, there was a decrease in the SGRQ total score from baseline averaged over the 52-week  treatment  period,  indicating  an  improvement  with  triple  and  dual  treatment  (adjusted  mean changes  of  -3.20  and  -1.52  units,  respectively;  p&lt;0.001  in  both  cases)  (Figure  6).  CHF  5993  pMDI resulted in a greater improvement in this health-related quality of life (HRQoL) tool as evidenced by the adjusted  mean  difference  between  treatments  of  -1.68  units  (95%CI  [-2.55;  -0.81],  p&lt;0.001).  The greatest improvements were observed in the SGRQ symptoms and impact scores.

Figure 7: Adjusted mean change from baseline in SGRQ total score (ITT population)

<!-- image -->

CI = Confidence interval; ITT = Intention-to-treat; pMDI = Pressurised metered dose inhaler; R = Indacaterol/GB; SGRQ = St. George's Respiratory Questionnaire; T = CHF 5993 pMD1.

&gt;  s    s       na s s

<div style=\"page-break-after: always\"></div>

Table 12: SGRQ responders at Week 26 and Week 52 - ITT population

<!-- image -->

|               |                                  |                     | CHF 5993 pMDI N=764   | Indacaterol/GB N=768   |
|---------------|----------------------------------|---------------------|-----------------------|------------------------|
| Week 26       | Week 26                          | Week 26             |                       |                        |
| Responder     | n (%)                            | n (%)               | 310 (40.6)            | 292 (38.0)             |
| Responder     | CHF 5993 pMDI vs. Indacaterol/GB | Odds ratio (95% CI) | 1.130 (0.915, 1.395)  | 1.130 (0.915, 1.395)   |
| Responder     | CHF 5993 pMDI vs. Indacaterol/GB | p-value             | 0.255                 | 0.255                  |
| Non-responder | n (%)                            | n (%)               | 454 (59.4)            | 476 (62.0)             |
| Non-responder | Change > -4                      | n (%)               | 412 (53.9)            | 424 (55.2)             |
| Non-responder | Missing data                     | n (%)               | 42 (5.5)              | 52 (6.8)               |
| Week 52       | Week 52                          | Week 52             | Week 52               | Week 52                |
| Responder     | n (%)                            | n (%)               | 311 (40.7)            | 279 (36.3)             |
| Responder     | CHF 5993 pMDI                    | Odds ratio (95% CI) | 1.220 (0.985,1.511)   | 1.220 (0.985,1.511)    |
| Responder     | vs. Indacaterol/GB               | p-value             | 0.068                 | 0.068                  |
| Non-responder | n (%)                            | n (%)               | 453 (59.3)            | 489 (63.7)             |
| Non-responder | Change > -4                      | n (%)               | 356 (46.6)            | 375 (48.8)             |
| Non-responder | Missing data                     | n (%)               | 97 (12.7)             | 114 (14.8)             |

CI = Confidence interval; GB = Glycopyrronium bromide; ITT = Intention-to-treat; pMDI = Pressurised metered dose inhaler; SGRQ = St. George's Respiratory Questionnaire; vs. = Versus

N = Number of patients in the ITT population; n = Number of patients with available data.

a SGRQ response = Change from baseline in total score ≤ -4; non-response = Change from baseline in total score &gt; -4 or missing data.

<div style=\"page-break-after: always\"></div>

## Use of Rescue Medication (Secondary endpoint)

Table 13: Change from baseline in the percentage of days, nights and complete days without rescue medication intake - ITT population

<!-- image -->

## Ancillary analyses

N/A

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 14: Summary of Efficacy for study TRIPLE 8

| Title: A 52-week, double blind, double dummy, randomized, multinational, multicentre, 2-arm parallel group, active controlled clinical trial of fixed combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide administered via pMDI (CHF 5993) versus indacaterol/glycopyrronium (Ultibro®) via DPI in patients with Chronic Obstructive Pulmonary Disease (TRIBUTE)   | Title: A 52-week, double blind, double dummy, randomized, multinational, multicentre, 2-arm parallel group, active controlled clinical trial of fixed combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide administered via pMDI (CHF 5993) versus indacaterol/glycopyrronium (Ultibro®) via DPI in patients with Chronic Obstructive Pulmonary Disease (TRIBUTE)   | Title: A 52-week, double blind, double dummy, randomized, multinational, multicentre, 2-arm parallel group, active controlled clinical trial of fixed combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide administered via pMDI (CHF 5993) versus indacaterol/glycopyrronium (Ultibro®) via DPI in patients with Chronic Obstructive Pulmonary Disease (TRIBUTE)   | Title: A 52-week, double blind, double dummy, randomized, multinational, multicentre, 2-arm parallel group, active controlled clinical trial of fixed combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide administered via pMDI (CHF 5993) versus indacaterol/glycopyrronium (Ultibro®) via DPI in patients with Chronic Obstructive Pulmonary Disease (TRIBUTE)   | Title: A 52-week, double blind, double dummy, randomized, multinational, multicentre, 2-arm parallel group, active controlled clinical trial of fixed combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide administered via pMDI (CHF 5993) versus indacaterol/glycopyrronium (Ultibro®) via DPI in patients with Chronic Obstructive Pulmonary Disease (TRIBUTE)   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                                                                               | CCD-05993AA1-08 EudraCT no. 2014-001704-22                                                                                                                                                                                                                                                                                                                                                                     | CCD-05993AA1-08 EudraCT no. 2014-001704-22                                                                                                                                                                                                                                                                                                                                                                     | CCD-05993AA1-08 EudraCT no. 2014-001704-22                                                                                                                                                                                                                                                                                                                                                                     | CCD-05993AA1-08 EudraCT no. 2014-001704-22                                                                                                                                                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                                                                                                                                                                                                                         | double blind, double dummy, randomized, multinational, multicentre, 2-arm parallel group, active controlled clinical trial                                                                                                                                                                                                                                                                                     | double blind, double dummy, randomized, multinational, multicentre, 2-arm parallel group, active controlled clinical trial                                                                                                                                                                                                                                                                                     | double blind, double dummy, randomized, multinational, multicentre, 2-arm parallel group, active controlled clinical trial                                                                                                                                                                                                                                                                                     | double blind, double dummy, randomized, multinational, multicentre, 2-arm parallel group, active controlled clinical trial                                                                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                                                                                                                                                                                                                         | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                 | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                 | 52 weeks 2 weeks <not applicable>                                                                                                                                                                                                                                                                                                                                                                              | 52 weeks 2 weeks <not applicable>                                                                                                                                                                                                                                                                                                                                                                              |
| Hypothesis                                                                                                                                                                                                                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                                                                                                                                                                                                                    | Superiority                                                                                                                                                                                                                                                                                                                                                                                                    | Superiority                                                                                                                                                                                                                                                                                                                                                                                                    | Superiority                                                                                                                                                                                                                                                                                                                                                                                                    |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                              | CHF 5993 pMDI (test)                                                                                                                                                                                                                                                                                                                                                                                           | CHF 5993 pMDI (test)                                                                                                                                                                                                                                                                                                                                                                                           | fixed dose combination (BDP+FF+GB) 2 puffs b.i.d. 100/6/12.5 µg per actuation (nominal daily dose: 400/24/50 µg) 52 weeks                                                                                                                                                                                                                                                                                      | fixed dose combination (BDP+FF+GB) 2 puffs b.i.d. 100/6/12.5 µg per actuation (nominal daily dose: 400/24/50 µg) 52 weeks                                                                                                                                                                                                                                                                                      |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                              | IND/GB DPI (reference)                                                                                                                                                                                                                                                                                                                                                                                         | IND/GB DPI (reference)                                                                                                                                                                                                                                                                                                                                                                                         | N=764 randomised fixed dose combination (IND+GB) 1 capsule once daily 85/43 µg per capsule (nominal daily dose: 85/43 µg) 52 weeks N=768 randomised                                                                                                                                                                                                                                                            | N=764 randomised fixed dose combination (IND+GB) 1 capsule once daily 85/43 µg per capsule (nominal daily dose: 85/43 µg) 52 weeks N=768 randomised                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                      | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                               | COPD exacerbation rate                                                                                                                                                                                                                                                                                                                                                                                         | adjusted rate of moderate to severe COPD exacerbations per patient per year                                                                                                                                                                                                                                                                                                                                    | adjusted rate of moderate to severe COPD exacerbations per patient per year                                                                                                                                                                                                                                                                                                                                    |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                      | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                             | Time to first exacerbation                                                                                                                                                                                                                                                                                                                                                                                     | time to first moderate-to-severe exacerbation and time to first severe exacerbation                                                                                                                                                                                                                                                                                                                            | time to first moderate-to-severe exacerbation and time to first severe exacerbation                                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                      | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                             | Number of COPD exacerbations                                                                                                                                                                                                                                                                                                                                                                                   | adjusted rate of moderate / severe COPD exacerbations                                                                                                                                                                                                                                                                                                                                                          | adjusted rate of moderate / severe COPD exacerbations                                                                                                                                                                                                                                                                                                                                                          |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                      | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                             | trough FEV1                                                                                                                                                                                                                                                                                                                                                                                                    | Change from baseline in trough FEV1 at each visit and over the entire treatment period; trough FEV1 response ≥ 100 mLat weeks 26 and 52;                                                                                                                                                                                                                                                                       | Change from baseline in trough FEV1 at each visit and over the entire treatment period; trough FEV1 response ≥ 100 mLat weeks 26 and 52;                                                                                                                                                                                                                                                                       |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                      | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                             | SGRQ                                                                                                                                                                                                                                                                                                                                                                                                           | change from baseline at each visit and over the entire treatment period (total score and domain scores); SGRQresponse ≤ -4 at weeks 26 and 52                                                                                                                                                                                                                                                                  | change from baseline at each visit and over the entire treatment period (total score and domain scores); SGRQresponse ≤ -4 at weeks 26 and 52                                                                                                                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                      | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                             | use of rescue medication                                                                                                                                                                                                                                                                                                                                                                                       | change from baseline in the days / nights / complete days without intake of rescue medication; data on quantitative use of rescue medication change from baseline at each visit and over the entire treatment period                                                                                                                                                                                           | change from baseline in the days / nights / complete days without intake of rescue medication; data on quantitative use of rescue medication change from baseline at each visit and over the entire treatment period                                                                                                                                                                                           |
| Database lock                                                                                                                                                                                                                                                                                                                                                                                                  | 24 August 2017                                                                                                                                                                                                                                                                                                                                                                                                 | 24 August 2017                                                                                                                                                                                                                                                                                                                                                                                                 | 24 August 2017                                                                                                                                                                                                                                                                                                                                                                                                 | 24 August 2017                                                                                                                                                                                                                                                                                                                                                                                                 |
| Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                           |
| Analysis description                                                                                                                                                                                                                                                                                                                                                                                           | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                               | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                               | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                               | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                               |
| Analysis population and time point description                                                                                                                                                                                                                                                                                                                                                                 | ITT, week 52, test versus reference                                                                                                                                                                                                                                                                                                                                                                            | ITT, week 52, test versus reference                                                                                                                                                                                                                                                                                                                                                                            | ITT, week 52, test versus reference                                                                                                                                                                                                                                                                                                                                                                            | ITT, week 52, test versus reference                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                                                                                                                                | Treatment groups                                                                                                                                                                                                                                                                                                                                                                                               | CHF                                                                                                                                                                                                                                                                                                                                                                                                            | 5993 pMDI (test)                                                                                                                                                                                                                                                                                                                                                                                               | IND/GB DPI (reference)                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                      | adjusted rate of moderate-to-severe exacerbations                                           | adjusted rate of moderate-to-severe exacerbations                                           | adjusted rate of moderate-to-severe exacerbations                                           |
|----------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
|                      | Number of subjects                                                                          | N=764                                                                                       | N=768                                                                                       |
|                      | point estimator                                                                             | 0.504                                                                                       | 0.595                                                                                       |
|                      | 95%CI                                                                                       | [0.447; 0.569] [0.530; 0.668]                                                               | [0.447; 0.569] [0.530; 0.668]                                                               |
|                      | adjusted rate ratio (95%CI)                                                                 | 0.848 [0.723; 0.995]                                                                        | 0.848 [0.723; 0.995]                                                                        |
| Analysis description | p=0.043 Secondary analysis                                                                  | p=0.043 Secondary analysis                                                                  | p=0.043 Secondary analysis                                                                  |
|                      | time to first moderate-to-severe exacerbation                                               | time to first moderate-to-severe exacerbation                                               | time to first moderate-to-severe exacerbation                                               |
|                      | Number of subjects                                                                          | N=764                                                                                       | N=768                                                                                       |
|                      | Cox hazard ratio (95%CI)                                                                    | 0.901 [0.763; 1.064]                                                                        | 0.901 [0.763; 1.064]                                                                        |
|                      | adjusted rate of moderate exacerbations per patient and year                                | adjusted rate of moderate exacerbations per patient and year                                | adjusted rate of moderate exacerbations per patient and year                                |
|                      | Number of subjects                                                                          | N=764                                                                                       | N=768                                                                                       |
|                      | point estimator                                                                             | 0.408                                                                                       | 0.471                                                                                       |
|                      | 95%CI                                                                                       | [0.356; 0.468] [0.413; 0.537]                                                               | [0.356; 0.468] [0.413; 0.537]                                                               |
|                      |                                                                                             | 0.866 [0.723; 1.037] p=0.118                                                                | 0.866 [0.723; 1.037] p=0.118                                                                |
|                      | adjusted rate of severe exacerbations per patient and year                                  | adjusted rate of severe exacerbations per patient and year                                  | adjusted rate of severe exacerbations per patient and year                                  |
|                      | Number of subjects                                                                          | N=764                                                                                       | N=768                                                                                       |
|                      | point estimator                                                                             | 0.074                                                                                       | 0.094                                                                                       |
|                      | 95%CI                                                                                       | [0.055; 0.099] [0.072; 0.123]                                                               | [0.055; 0.099] [0.072; 0.123]                                                               |
|                      | adjusted rate ratio (95%CI)                                                                 | 0.787 [0.551; 1.125] p=0.189                                                                | 0.787 [0.551; 1.125] p=0.189                                                                |
|                      | change from baseline in pre-dose morning FEV1 (in L) as averaged over the treatment period  | change from baseline in pre-dose morning FEV1 (in L) as averaged over the treatment period  | change from baseline in pre-dose morning FEV1 (in L) as averaged over the treatment period  |
|                      | Number of subjects                                                                          | N=764                                                                                       | N=768                                                                                       |
|                      | point estimator                                                                             | -0.003                                                                                      | -0.026                                                                                      |
|                      | 95%CI                                                                                       | [-0.016; 0.010] [-0.039; -0.013]                                                            | [-0.016; 0.010] [-0.039; -0.013]                                                            |
|                      | (95%CI) p=0.018 change from baseline in SGRQ total over the entire treatment period         | [0.004; 0.040]                                                                              | [0.004; 0.040]                                                                              |
|                      | score (in units)                                                                            | score (in units)                                                                            | score (in units)                                                                            |
|                      | Number of subjects                                                                          | N=764                                                                                       | N=768                                                                                       |
|                      | point estimator                                                                             | -3.20                                                                                       | -1.52                                                                                       |
|                      | 95%CI                                                                                       | [-3.81; -2.58] [-2.13; -0.90]                                                               | [-3.81; -2.58] [-2.13; -0.90]                                                               |
|                      | adjusted mean difference (95%CI)                                                            | -1.68 [-2.55; -0.81]                                                                        | -1.68 [-2.55; -0.81]                                                                        |
|                      | p<0.001 SGRQ total score responders (change from baseline ≤ -4) at week 52 (ITT population) | p<0.001 SGRQ total score responders (change from baseline ≤ -4) at week 52 (ITT population) | p<0.001 SGRQ total score responders (change from baseline ≤ -4) at week 52 (ITT population) |
|                      | Number of subjects                                                                          | N=764                                                                                       | N=768                                                                                       |
|                      | Responder (N /%)                                                                            | 311 (40.7)                                                                                  | 279 (36.3)                                                                                  |
|                      | Odds ratio (95%CI) p=0.068                                                                  | 1.220 [0.985; 1.511]                                                                        | 1.220 [0.985; 1.511]                                                                        |

<div style=\"page-break-after: always\"></div>

|       | change from baseline in %age of days without rescue medication intake over randomized treatment period   | change from baseline in %age of days without rescue medication intake over randomized treatment period   | change from baseline in %age of days without rescue medication intake over randomized treatment period   |
|-------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
|       | Number of subjects                                                                                       | N=764                                                                                                    | N=768                                                                                                    |
|       | point estimator                                                                                          | 5.53                                                                                                     | 7.01                                                                                                     |
|       | 95%CI                                                                                                    | [3.48; 7.58]                                                                                             | [4.96; 9.06]                                                                                             |
|       | adjusted mean difference (95%CI)                                                                         | -1.47 [-4.37; 1.42]                                                                                      | -1.47 [-4.37; 1.42]                                                                                      |
| Notes |                                                                                                          |                                                                                                          |                                                                                                          |

## Analysis performed across trials (pooled analyses and meta-analysis)

N/A

## Clinical studies in special populations

N/A

## Supportive study TRIPLE 7

The  design  of  the  study  substantially  differs  from  that  of  other  phase III-IIIb  studies,  namely  by  the open-label treatment and the shorter total treatment duration of 26 weeks only (thereby not preventing seasonal influences on the exacerbation rate).

The  main  objective  of  the  open-label,  active-controlled  study  TRIPLE  7  was  to  demonstrate  that TRYDONIS  /  RIARIFY  is  non-inferior  to  commercially  available,  extemporary  triple  therapy  (fixed combination  of  fluticasone  and  vilanterol  plus  tiotropium)  in  terms  of  a  single  primary  endpoint,  the St. George's Respiratory Questionnaire (SGRQ) total score as a measure of health-related quality of life (HRQoL).

For that purpose, the change from baseline in SGRQ at week 26 of treatment was compared. Based on scientific literature and available clinical evidence, the putative MCID of 4 units for the total SGRQ score was chosen as the non-inferiority margin (i.e. upper limit of the two-sided 95% CI &lt;4 units, one-sided significance level of 0.025). Since non-inferiority was to be demonstrated, the MAH postulated that PP and ITT populations had equal importance for the statistical analysis of the primary efficacy variable.

Secondary objectives were to evaluate the effect of CHF5993 pMDI on lung function parameters, patient's health  status  and  on  clinical  outcome  measures,  to  assess  the  impact  of  study  treatments  on  health economic  outcomes,  and  to  evaluate  the  overall  safety  and  tolerability  of  the  administered  study treatments.

After  a  2-week  open-label  run-in  period  of  tiotropium  (18 μg/day), patients  were  randomised  in  a  1:1 ratio to receive one of the following open-label treatments for 26 weeks:

-  CHF5993 pMDI 100/6/12.5 μg (delivered dose: 87/5/9 μg BDP/FF/GB), 2 puffs twice daily (total daily nominal dose: 400/24/50 μg BDP/FF/GB);
-  fluticasone/vilanterol 100/25 μg DPI (delivered dose: 92/22 μg fluticasone furoate/vilanterol trifenatate), 1 inhalation once daily plus tiotropium 18 μg inhalation powder (delivered dose by hard capsule: 10 μg tiotropium bromide), 1 capsule once daily.

Subsequent visits were performed after 4 weeks (V3), 12 weeks (V4) and 26 weeks (V5) of treatment and a follow-up call 1 week after V5.

## Patient characteristics

<div style=\"page-break-after: always\"></div>

Starting on 29MAY2015 (FPFV), a total of 1477 patients were screened, of whom 1157 were randomised to  either  CHF5993  pMDI  (N=578)  or  fluticasone/vilanterol  plus  tiotropium  (N=579).  The  majority  of patients (94.6%) completed the study (LPLV on 05 January 2017). Overall, the probability of premature discontinuation from the study was comparable in the two treatment groups.

Demographic  characteristics were  comparable  between  treatment  groups.  Patients  enrolled  were predominantly white and male (N=874, 75.5%), the mean age was 63.9 years (53.5% aged &lt;65 years, 37.2% aged between 65 and 74 years and 9.3% aged ≥75 years).

On  average,  patients  were  diagnosed  with  COPD  about  8 years  prior  to  enrolment  with  no  relevant between-group differences (8.1 years in group CHF5993 pMDI and 7.7 years in group fluticasone/vilanterol + tiotropium). Patients were either current or ex-smokers, with an overall mean of 37.7 pack-years  and  a  mean  smoking  duration  of  38.6 years.  Only  a  small  percentage  of  patients changed their smoking status during the study.

At study entry, disease severity was comparable and the majority of patients were on double treatment, combining either a LABA with an ICS (73.5% vs. 72.5% of patients) or two bronchodilators (LABA / LAMA 18.7% vs. 19.3%). LAMA monotherapy was taken by 7.4% of patients in each group.

The  mean  number  of  COPD  exacerbations  in  the  previous  year  was  comparable  in  the  two  treatment groups, with a vast majority of patients having one such episode recorded in their medical files. About 20% of patients had very severe airflow limitation as demonstrated by an FEV1 of &lt;30% of the predicted normal value.

## Results

A  total  of  1157 patients  were  randomized  at  103 recruiting  sites  in  12 countries  (Belgium,  Germany, Hungary, Lithuania, Netherlands, Poland, Romania, Russia, South Africa, Sweden, Turkey, and UK):

-  CHF 5993 pMDI: N=578 patients
-  fluticasone/vilanterol + tiotropium N=579 patients

The  majority  of  patients  in  both  groups  completed  the  study  as  planned  by  the  clinical  trial  protocol (94.3% vs. 94.8%).

At baseline, the mean SGRQ total score was comparable in both groups (SGRQ total scores of 52.7 and 53.0  in  groups CHF  5993  pMDI  and  fluticasone /  vilanterol  plus  tiotropium,  respectively).  With  both treatments and independent of the analysis population, there was a (clinically) significant adjusted mean decrease  from  baseline  in  SGRQ  total  score  (-6.82 units  vs.  -7.82 units),  indicating  that  the  healthrelated  patient  status  had  improved  over  the  26-week  treatment  period  in  both  groups  (Table  15  and Table 16.

The  adjusted  mean  difference  between  groups  was  in  favour  of  group  fluticasone/vilanterol  plus tiotropium  (i.e.  slightly  more  important  improvement  under  the  extemporaneous  triple  therapy),  but since the upper 95% confidence interval of the adjusted mean difference was &lt;4 units (i.e. 2.64 units in the PP analysis and 2.65 units in the ITT analysis), from a formal point of view the non-inferiority of CHF 5993 pMDI over extemporary triple therapy (fluticasone / vilanterol plus tiotropium) was demonstrated.

Results of sensitivity and post hoc stratified analyses confirmed the overall conclusions of the trial (Figure 8).

At week 26, about 50% of patients in both treatment groups were responders, i.e. had a change from baseline  in  the  total  SGRQ  score  of ≤-4 units  (51.3%  vs.  53.1%;  odds  ratio  0.929,  95%CI  [0.728; 1.186];  PP  population).  Statistically  significant  improvements  were  seen  in  each  of  the  three  SGRQ domain scores (symptoms, impact, and activity scores).

<div style=\"page-break-after: always\"></div>

Table 15: Change from baseline in the SGRQ total score at week 26 (PP population)

|          |                                          |                                   | CHF 5993 pMDI N=559   | Fluticasone/vilanterol + tiotropium N=557   |
|----------|------------------------------------------|-----------------------------------|-----------------------|---------------------------------------------|
| Baseline | Baseline                                 | n                                 | 559                   | 557                                         |
|          |                                          | Mean (SD)                         | 52.61 (16.77)         | 52.76 (17.34)                               |
| Week 26  | Actual values                            | n                                 | 537                   | 532                                         |
| Week 26  |                                          | Mean (SD)                         | 45.79 (18.06)         | 44.64 (18.19)                               |
| Week 26  | Change from baseline                     | n                                 | 537                   | 532                                         |
| Week 26  |                                          | Mean (SD)                         | -6.80 (14.97)         | -7.84 (15.06)                               |
| Week 26  |                                          | Adjusted mean (95% CI)            | -6.82 (-7.97; -5.66)  | -7.82 (-8.98; -6.66)                        |
| Week 26  |                                          | p-value                           | <0.001                | <0.001                                      |
| Week 26  | CHF 5993 pMDI vs. fluticasone/vilanterol | Adjusted mean difference (95% CI) | 1.00 (-0.64; 2.64)    | 1.00 (-0.64; 2.64)                          |
| Week 26  | + tiotropium                             | p-value                           | 0.231                 | 0.231                                       |

CI = Confidence interval; pMDI = Pressurised metered dose inhaler; PP = Per=protocol; SD = Standard deviation; SGRQ =

St. George's Respiratory Questionnaire; vs. = Versus.

N = Number of patients in the PP population; n = Number of patients with available data.

Table 16: Change from baseline in the SGRQ total score at week 26 (ITT population)

|          |                                                       |                                   | CHF 5993 pMDI N=577   | Fluticasone/vilanterol + tiotropium N=579   |
|----------|-------------------------------------------------------|-----------------------------------|-----------------------|---------------------------------------------|
| Baseline | Baseline                                              | n                                 | 577                   | 579                                         |
|          |                                                       | Mean (SD)                         | 52.72 (16.71)         | 52.96 (17.38)                               |
| Week 26  | Actual values                                         | n                                 | 553                   | 553                                         |
| Week 26  | Change from baseline                                  | Mean (SD) n                       | 45.97 (18.10)         | 44.86 (18.23)                               |
| Week 26  |                                                       |                                   | 553                   | 553                                         |
| Week 26  |                                                       | Mean (SD)                         | -6.76 (14.98)         | -7.80 (15.03)                               |
| Week 26  |                                                       | Adjusted mean (95% CI)            | -6.77 (-7.91; -5.64)  | -7.82 (-8.95; -6.68)                        |
| Week 26  |                                                       | p-value                           | <0.001                | <0.001                                      |
| Week 26  | CHF 5993 pMDI vs. fluticasone/vilanterol + tiotropium | Adjusted mean difference (95% CI) | 1.04 (-0.56; 2.65)    | 1.04 (-0.56; 2.65)                          |
| Week 26  |                                                       | p-value                           | 0.204                 | 0.204                                       |

CI = Confidence interval; ITT = Intention-to-treat; pMDI = Pressurised metered dose inhaler; SD = Standard deviation;

SGRQ = St. George's Respiratory Questionnaire; vs. = Versus.

N = Number of patients in the ITT population; n = Number of patients with available data.

<div style=\"page-break-after: always\"></div>

Figure 8: Forest plot for the adjusted mean differences between treatments in the SGRQ total score at week 26

<!-- image -->

At  baseline,  the  mean  pre-dose  morning  FEV1  was  comparable  between  treatments  (1.093 L  in  group CHF5993 pMDI and 1.111 L in group fluticasone/vilanterol + tiotropium). A statistically significant mean increase from baseline in pre-dose morning FEV1 was observed in both groups (0.060 L vs. 0.108 L, PP population),  the  between-group  difference  reaching  statistical  significance  and  favoring  the  reference group at week 26 (adjusted mean difference -0.048 L, 95%CI [-0.077; -0.019], p=0.002, PP population).

When  calculating  FEV1  responder  rates,  CHF5993  pMDI  was  statistically  significantly  inferior  to  the reference treatment when higher cut-off values were used, i.e. the percentage of patients with relevant improvements in FEV1 of ≥100 mL (Table 17) or ≥120 mL (not shown).

Figure 9: Adjusted mean change from baseline in pre-dose morning FEV1 in L (PP population)

<!-- image -->

SourceData:Table14.2.4.4

Notes: [1] Bars represent 95% C1.

[2] * Statistically significant difference between treatments (p-value &lt; 0.05)

<div style=\"page-break-after: always\"></div>

Table 17: FEV1 responders and respective odds ratio at week 26 as based on cut-off (change from baseline in pre-dose morning FEV1 ≥ 100 mL; PP population)

<!-- image -->

|                                                                                                                                                                                                                                                                                                                                                                                 | CHF 5993 pMDI (N=559)                                                                                                                                                                                                                                                                                                                                                           | Fluticasone/vilanterol+ tiotropium (N=557)                                                                                                                                                                                                                                                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Responders                                                                                                                                                                                                                                                                                                                                                                      | 203 (36.3)                                                                                                                                                                                                                                                                                                                                                                      | 238 (42.7)                                                                                                                                                                                                                                                                                                                                                                      |
| Non-Responders                                                                                                                                                                                                                                                                                                                                                                  | 356 (63.7)                                                                                                                                                                                                                                                                                                                                                                      | 319 (57.3)                                                                                                                                                                                                                                                                                                                                                                      |
| Change<100mL                                                                                                                                                                                                                                                                                                                                                                    | 332 (59.4)                                                                                                                                                                                                                                                                                                                                                                      | 290 (52.1)                                                                                                                                                                                                                                                                                                                                                                      |
| Missing data                                                                                                                                                                                                                                                                                                                                                                    | 24 (4.3)                                                                                                                                                                                                                                                                                                                                                                        | 29 (5.2)                                                                                                                                                                                                                                                                                                                                                                        |
| Source Data: Listing 16.2.6.4.1 pre-dosemorninglFEvl< 1oomLormissing data. [2] Table presents number and percentage of patients (n (&)). [3] Percentages are based on the number of patients in the relevant treatment/population (N). [4]Data from patients who discontinued prematurely and performed the Visit 5 assessments are re-allocated to the most appropriate visit. | Source Data: Listing 16.2.6.4.1 pre-dosemorninglFEvl< 1oomLormissing data. [2] Table presents number and percentage of patients (n (&)). [3] Percentages are based on the number of patients in the relevant treatment/population (N). [4]Data from patients who discontinued prematurely and performed the Visit 5 assessments are re-allocated to the most appropriate visit. | Source Data: Listing 16.2.6.4.1 pre-dosemorninglFEvl< 1oomLormissing data. [2] Table presents number and percentage of patients (n (&)). [3] Percentages are based on the number of patients in the relevant treatment/population (N). [4]Data from patients who discontinued prematurely and performed the Visit 5 assessments are re-allocated to the most appropriate visit. |
| odds Ratio（95CI）;p-value (CHF5993pMDI/ Fluticasone/vilanterol+ tiotropium)                                                                                                                                                                                                                                                                                                      | 0.737(0.577,                                                                                                                                                                                                                                                                                                                                                                    | 0.943);0.015*                                                                                                                                                                                                                                                                                                                                                                   |

## 2.4.3.  Discussion on clinical efficacy

The  currently  approved  indication  wording  ' …[COPD  patients]  who  are  not  adequately  treated  by  a combination of an inhaled corticosteroid and a long-acting β2-agonist ' highlights the lack of evidence to claim a step-up indication from the combination of a long-acting muscarinic receptor antagonist (LAMA) and a long-acting beta2 agonist (LABA) due to the absence of the combination of LAMA and LABA as comparator in the pivotal Phase III study at time of the MAA of TRYDONIS / RIARIFY, a triple combination of an inhaled corticosteroid (ICS), and LABA and LAMA.

The  MAH  is  now  applying  for  a  broader  indication  including  newly  a  step-up  indication  from  the combination of a LAMA and LABA (e.g. Indacaterol/GB). Two completed clinical safety and efficacy trials (one pivotal study TRIPLE 8 and one supportive study TRIPLE 7) in support of the extension of variation are presented.

In studies TRIPLE 7 and TRIPLE 8, a total of 1157/1532 patients were randomised at 103/187 sites in 12/17 countries, respectively.

A  single  two-day  systems  audit  covering  both  studies  (TRIPLE  7  and  TRIPLE  8)  and  three  site  audits covering TRIPLE 8 (each lasting for one to two days only) were performed by or on behalf of the MAH. Moreover, (routine?) inspections were performed at unidentified sites by local authorities in Austria and Latvia.  The  MAH  claims  that  the  annual  audit  plan  /  programme  follows  a  risk-based  approach;  SOP DRQA-SP-11-008 - Audits of Clinical Trials however permits to select clinical sites for an audit activity because  a  (routine)  health  authority  inspection  has  been  announced.  This  means  that  for  the  pivotal study TRIPLE 8, two out of three site visits / audits were performed in a reactive manner but not using a prospective, risk-based approach.

No  critical  observations  or  relevant  GCP  issues  were  identified  during  the  sponsor  audits  or  health authority inspections of the pivotal study TRIPLE 8.

For  study  TRIPLE  7,  critical  observations  were  reported  from  both  internal  audits  and  health  authority inspections. In the quality systems audit of the CRO's data management unit (ICON Clinical Research, South County Business Park, Dublin, Ireland) performed from 04 to 05NOV2015, a critical finding was identified, i.e. unsatisfactory oversight by project management. The impact or consequences of this nonconformity are not revealed. Reportedly, satisfactory CAPA measures were implemented.

This contrasts with the observation that in study TRIPLE 8 erroneous treatment compliance figures were distributed  prior  to  each  of  the  three  blinded  data  review  meeting,  making  it  necessary  to  modify  the assignment of six subjects to the PP population after unblinding.

<div style=\"page-break-after: always\"></div>

Overall, the MAH has undertaken limited efforts to assess and assure the reliability and integrity of the trial systems against own written standards and applicable laws and regulations. Annual audit plans / programmes were finalised with significant delay and for the pivotal study TRIPLE 8, only a single site audit was performed that followed a proactive and risk-based approach. This finding may challenge the internal validity of the study / data reliability.

## TRIPLE 8

## Design and conduct of clinical study

According to the most recent GOLD recommendation (update 2017), a dual bronchodilator therapy with a LABA plus LAMA is the first choice when treating patients with COPD who are symptomatic and at risk of exacerbations.  The  choice  of  the  active  comparator  in  TRIPLE  8  and  more  specifically  the  recently approved combination therapy (IND/GB, tradename Ultibro Breezehaler) is acceptable.

Eligibility criteria in study TRIPLE 8 were comparable to those defined for the pivotal studies included in the application to obtain the initial MAs of TRYDONIS / RIARIFY. Though the severity of airflow limitation is no longer used as a criterion for the COPD severity classification by the GOLD update 2017, patients enrolled  in  TRIPLE  8  belonged  to  GOLD  groups  B  and  D  as  based  on  their  symptom  severity  and exacerbation  risk.  Study  patients  were  thus  at  the  more  severe  end  of  the  COPD  spectrum  and symptomatic despite dual therapy.

Of  note,  there  was  no  step  down  in  treatment  upon  enrolment.  Solely  patients  already  receiving  dual treatment or LAMA monotherapy were included.

As  was  the  case  for  prior  studies,  the  MAH  excluded  patients  with  clinically  significant  cardiovascular conditions from study participation, e.g. those with unstable ischaemic heart disease, NYHA Class III/IV left ventricular failure, acute ischaemic heart disease in the year prior to the screening examination or a history of sustained cardiac arrhythmias. In combination with the limited number of patients enrolled, this limits the assessment of the cardiovascular safety of the compound.

##  Outcomes/endpoints

## Primary endpoint

Study TRIPLE 8 had a single primary outcome, i.e. the rate of moderate-to-severe COPD exacerbations over  52  weeks  of  treatment.  Measuring  the  rate  of  moderate  and  severe  COPD  exacerbations  is  an accepted primary endpoint as the prevention/reduction of such events is recognised to be a primary goal of COPD therapy, due to the important negative impact of such events on health status, health-related QoL, and disease progression. The definition of what represents a COPD exacerbation was in line with the one  proposed  by  the  respective  EMA/CHMP  guideline  issued  in  2012.  A  number  of  clarifications  and refinements were included in the clinical trial protocol which appears acceptable.

Overall, it is acknowledged that the primary endpoint chosen was a clinically relevant one. However, the EMA  guidance  document's  recommendation  to  have  all  exacerbation  episodes  evaluated  by  a  blinded external adjudication committee was not followed. Instead, an arbitrary numerical criterion (i.e. a 10 day time gap) was defined in the SAP in order to decide whether an episode was a new event rather than being a relapse or continuation of a previously recorded one. The applicant confirmed that the arbitrary 10-day time gap for the primary exacerbation endpoint was chosen early in line with previous studies (e.g.  TRIPLE  5  and  TRIPLE  6)  and  already  specified  in  the  first  draft  version  of  the  SAP  (v0.1  dated 21DEC2015).

<div style=\"page-break-after: always\"></div>

No attempts were made by the MAH to follow all patients for the full duration of the study and to record subsequent exacerbation events, should they have stopped IMP intake. Instead, the log-time in the study was  included  as  offset  in  the  negative  binomial  model  used  for  the  analysis  of  the  primary  response variable. This seems to be acceptable as 88.7% of patients in the TRYDONIS / RIARIFY and 85.4% in the IND/GB group completed more than 48 weeks of treatment, and 87.2% and 84.4% in the CHF 5993 pMDI and IND/GB groups respectively completed at ≥52 weeks of treatment (source: Table 14.3.1.1).

The  MAH  was  requested  to  make  available  a  copy  of  report  resulting  from  the  blinded  data  review meeting (Chiesi terminology: Data Review Report) which is repeatedly referenced in the Clinical study report and its appendices. From the requested documentation it becomes apparent that the secondary population for analysis (i.e. the per-protocol population) was modified after unblinding. The reason given by the applicant is an error in the reported treatment compliance values for a total of six patients. Five of them were classified post hoc to be major protocol violators (and thus excluded from the PP analysis), and  another  one  confirmed  to  have  adequate  compliance  (and  thus  included  in  the  PP  analysis). Reportedly, this was done by applying the same pre-defined criteria as for other patients.

The post hoc modifications applied to the PP population appear to have had no impact on the primary results of the study, but quality problem. The criticality of this observation also appears to result more from the fact that this important incident (i.e. unblinded modification of the per-protocol population) was omitted  and  not  made  transparent  in  the  final  CSR.  Instead,  the  false  impression  was  given  that  all decisions were taken and the populations to be used in the analysis entirely defined prior to database lock and prior to unblinding. In its response, the applicant however agreed that this incident should have been made transparent in the clinical study report of study TRIPLE 8 and the overall submission.

Patients  in  both  groups  were  comparable  in  terms  of  demography  and  baseline  characteristics,  in particular  COPD  history.  In  accordance  with  inclusion  criterion  #6,  patients  received  either  mono-  or double therapy, but no triple therapy prior to study entry. Thus, in this study there was no step-down in therapy upon randomisation which might have penalised the comparator group.

The study population is predominantly (Eastern) European and may be a representative sample though the  course  of  COPD  and  rate  of  exacerbations  may  be  influenced  by  country-level  socioeconomic  and environmental factors.

## Primary analysis and sensitivity analyses

Over 52 weeks of treatment, less patients in group TRYDONIS / RIARIFY experienced less moderate-tosevere  exacerbations  (35.7%,  433  events)  as  compared  with  IND/GB  (37.5%,  485  events)  (ITT population).  Thus,  the  adjusted  exacerbation  rate  per  patient  per  year  was  lower  with  TRYDONIS  / RIARIFY (0.504, 95% CI [0.447, 0.569]) as compared with IND/GB (0.595 [0.530, 0.668]). The resulting adjusted  rate  ratio  was  0.848  (95%  CI  [0.723,  0.995]),  thereby  formally  confirming  a  statistically significant  reduction  of  15.2%  in  the  rate  of  moderate-to-severe  COPD  exacerbations  and  thus  the superiority of TRYDONIS / RIARIFY over IND/GB (p=0.043). Notable, the p-value of the primary analysis of  the  primary  endpoint  (ITT  dataset)  are  slightly  less  than  the  conventional  0.05  significance  level (p=0.043). The upper limit of the 95% CI for the adjusted exacerbation rate ratio was 0.995. Results of the PP population confirmed the estimated effect size, but barely missed statistical significance (p=0.050, upper limit of 95% CI=1.000). Also, results of the additional sensitivity analyses (see below 'Definition of a single exacerbation') support the consistently borderline results for the primary endpoint. Depending on the analysis, results are non-significant or borderline significant. Furthermore, since a treatment policy estimand is of higher relevance than a hypothetical one, an analysis based on reference data (CR  or  J2R)  would  have  been  the  preferred  option  from  a  regulatory  point  of  view. Both reference-based imputation approaches failed to reach statistical significance (see below 'Missing data'). Overall,  although  treatment  effect  estimates  favour  TRYDONIS  /  RIARIFY,  the  study  results  are  not

<div style=\"page-break-after: always\"></div>

associated  with  the  statistically  compelling  evidence.  These  issues  are  further  discussed  in  the  overall conclusions of the clinical efficacy section.

## Clinical relevance

There is currently no consensus as to what constitutes the minimal clinical important difference (MCID) for COPD exacerbations as the impact of their reduction/prevention appears to be influenced by various factors, including but not limited to the choice of the comparator, baseline status/characteristics of the patient  population  assessed  as  well  as  by  the  definitions  used  for  grading  exacerbation  severity  and frequency. Recently, Chapman and coll. (2013) suggested that interventions reducing exacerbations by as little  as  11%  may be considered as clinically relevant. In TRIPLE 8 study, the rate of moderate-tosevere COPD exacerbations over 52 weeks was lower with BDP/FF/GB than with IND/GB, with a rate ratio of 0.848 (95% CI [0.723, 0.995], p-value=0.043) indicating a 15% reduction in the exacerbation rate. However, it should be stressed that this difference, in absolute terms (an estimated reduction in 0.09 exacerbations  per  patient  per  year,  from  0.594  with  LABA/LAMA  to  0.504  with  the  triple  therapy),  is considered modest from a clinical perspective. It is conceded that the chosen study design and population - in contrast to other recently published studies - did not penalise the comparator group nor did it inflate artificially the rate of moderate and severe COPD exacerbations.

When reviewing the data, an instance was seen where a fatal SAE in a patient of group CHF 5993 pMDI may not have been correctly classified and reported as COPD exacerbation. The case involves a 58-year old white male patient randomised to receive CHF5993 pMDI. The last study visit preceding the event was Visit 5, at week ´26. Reportedly, the patient experienced an event of acute respiratory failure (coded PT: acute respiratory failure ) and was successfully reanimated while transported to a hospital. More detailed clinical and laboratory diagnostic criteria (e.g. arterial blood gas test results) are not reported. The event was considered to be serious, severe in intensity, but not related to the study medication. The patient remained in a serious condition and died two days later from a second episode of cardiac arrest. Only a single COPD exacerbation of moderate intensity is reported for this patient. The acute respiratory failure did not result in recording an acute exacerbation of the underlying COPD.

The MAH was requested to comment on the case and to set out the reasons why it was excluded that the acute respiratory failure reported in patient was the result of an acute exacerbation of COPD. The MAH claims that the reason for the ICU admission and cardiopulmonary admission was a myocardial infarction and that the inappropriate SAE term reported by the investigator (preferred term, PT: «acute respiratory failure»)  was  not  further  challenged  by  the  MAH.  However,  according  to  applicable  guidance  of  how MedDRA  terms  should  be  selected,  the  triggering  event  and  preferably  a  diagnosis  (and  not  signs  / symptoms or sequelae) should be reported. No relevant pre-existing cardiovascular  conditions  besides mild hypertension were reported for this patient. The patient in question had already experienced a COPD exacerbation of moderate intensity. The reason for administering ceftriaxone sodium and metronidazole (dose and route for both unknown) during his 2-day ICU stay has not been addressed in the response.

Notable, in study TRIPLE 7, another patient had suddenly and unexpectedly died a few days only after having  had  an  uneventful  study  visit  3.  The  case  was  reported  by  the  investigator  as  «respiratory failure», but in this case autopsy results clearly pointed towards an acute and purulent infection of the lung as the direct cause of death. In spite of this evidence, the event was not counted by the MAH as an acute exacerbation of COPD. No compelling arguments and well-founded epicrisis were forwarded by the applicant  why  an  (acute)  infectious  pulmonary  event  (leading  to  an  acute  coronary  syndrome)  was excluded in a  patient. The applicant considers that ceftriaxone and metronidazole (dose unknown) were given during the two-day ICU stay to « prevent or treat ventilator-acquired pneumonia », but once notified of the event did not make an effort to confirm why these two antibiotics were administered. It is noted that  the  prophylactic  short-term  administration  of  antibiotics  is  not  a  recommendation  in  the  cited guidance document (Torres et al., 2018) and that there is no uniform management of intubated patients across Europe. As was also the case for one patient, the applicant did not challenge the AE term reported

<div style=\"page-break-after: always\"></div>

by the investigator  in  order  to  have  a  more  accurate  event  term  in  the  study  documentation,  i.e.  the triggering event or preferably a diagnosis.

Thus and in conclusion, based on these two examples, doubts remain on whether due care and diligence were exercised by the applicant (or its service providers) throughout trial conduct in fully assessing fatal / serious events and potential COPD exacerbations.

## Definition of a single exacerbation

In order to support the primary evaluation and the chosen time gap to define single exacerbations several additional analysis were requested and provided by the applicant.

Re-analysis  of  exacerbation  data  applying  different  time  gaps  to  define  single  exacerbations  overall support the borderline study results. Irrespective of the time gap applied, point estimates are very similar (slightly  smaller  for  time  gaps  &lt;10  days  and  slightly  larger  for  time  gaps  &gt;10)  and  borderline significant/non-significant depending on the time-gap applied (for 15 and 20 day time gaps results are not significant).

In  absence  of  a  blinded  external  adjudication  committee  to  define  single  exacerbations  and  given  the arbitrary rule to define two exacerbations periods as a single one if they are not more than 10 days apart, analyses  not  depending  on  the  specific  number  of  exacerbations  per  patients  were  requested;  in particular, analysis of the binary endpoint 'any exacerbation' and analysis of the number of exacerbation days  per  patient  were  provided.  The  proportion  of  patient  with  any  exacerbations  was  rather  similar between  both  groups  and  only  slightly  lower  for  TRYDONIS  /  RIARIFY  (35.7%  vs,  37.5%;  odds-ratio 0.918).  This  analysis  is  not  significant  due  to  the  low  treatment  difference  and  the  low  sample  size (power) for binary evaluation. Counting the number of exacerbation days per patient revealed on average a  lower  number  of  days  for  TRYDONIS  /  RIARIFY  (7.32  vs.  9.62).  Based  on  an  ANOVA  model  this difference of -2.3 was significant. Similar results were observed applying a negative binomial model to analyse exacerbation days. A rank ANOVA failed to show statistical significance by far; probably due to the  large  number  of  patients  without  exacerbations  (i.e.  zero  exacerbation  days).  These  tied  values (~63%) reduce the power of a rank based analysis. Given the low number of exacerbations per patient (around  95%  of  patients  had  0,  1  or  2  exacerbations)  evaluation  of  the  number  of  exacerbations  as categorical  variable  seems  a  reasonable  approach.  While  this  analysis  suggested  a  trend  in  favour  of TRYDONIS / RIARIFY it by far failed to reach statistical significance.

In  summary,  none  of  these  analyses  were  pre-specified  and  they  overall  show  and  support  the consistently borderline results for the evaluation of exacerbations. Treatment effect estimates are mostly similar and are depending on the analysis (borderline) significant or not-significant. Additional analyses overall support the consistency of borderline significant study results.

The primary analysis that was used targets a hypothetical estimand of the treatment effect if all subjects adhered  to  treatment.  Although  it  remains  unclear,  the  primary  analysis  is  apparently  based  on  ontreatment data only and no observation was recorded after treatment discontinuation. Hence, a treatment policy estimand on the treatment effect irrespective of treatment discontinuation is difficult to estimate.

The MAH clarified that patients were not planned to be followed up after treatment discontinuation. Still, some  patients  were  observed  after  they  stopped  treatment.  For  most  patients  the  follow-up  after treatment discontinuation (TD) was short. Total planned follow-up time over all patients was 763. 5 and 767.5 years for TRYDONIS / RIARIFY and comparator, respectively. Total on-treatment time (time prior to  TD)  was  716.3  and  707.4  years  and  total  off-treatment  time  (time  between  TD  and  study discontinuation) was 1.7 and 2.6 years. Furthermore, only 3 exacerbations occurred during off-treatment follow-up.

Hence, follow-up is overall rather complete. The analysis was based on the total follow-up time (including off-treatment  follow-up).  This  is  in  principle  supported,  but  given  that  off-treatment  follow-up  is extremely limited the primary analysis rather addresses a hypothetical effect had all patients adhered to

<div style=\"page-break-after: always\"></div>

study  treatment.  The  effect  regardless  of  treatment  discontinuations  (treatment  policy  estimand)  is considered of higher relevance as compared to the hypothetical estimand. However, in lack of sufficient off-treatment follow-up the treatment policy estimand is difficult to estimate. The most appropriate option in this situation would be to use multiple imputation based on reference data to cover the missing followup  time  (copy  reference  (CR)  and  jump  to  reference  (J2R)).  In  addition  to  an  analysis  based  on  ontreatment data only, these analyses were provided by the MAH and as expected (since only few patients were  not  completely  followed-up)  results  are  similar  for  all  analyses.  Point  estimates  only  range  from 0.846 to 0.859 and confidence intervals are also similar.  J2R  as  expected  yields  slightly  smaller  point estimates  as  compared  to  CR,  and  results  for  the  primary  analysis  and  the  MAR  based  imputation approach are almost identical  (due  to  being  based  on  the  same  assumption  and  addressing  the  same hypothetical estimand).

In summary, results of the additional analyses support the consistently borderline results for the primary exacerbation  endpoint.  Depending  on  the  analysis,  results  are  non-significant  or  borderline  significant. Furthermore,  since  a  treatment  policy  estimand  is  of  higher  relevance  than  a  hypothetical  one,  an analysis based on reference data (CR or J2R) would have been the preferred option from a regulatory point of view. Both reference-based imputation approaches failed to reach statistical significance.

The  MAH  investigated  the  heterogeneity  of  treatment  effects  across  different  subgroups  (including gender)  by  including  a  treatment  by  subgroup  interaction  term  into  the  analysis  as  requested  by  the CHMP (see annex 1, Q8) interactions were significant (p-values ≥ 0.25). Furthermore, forest plots do not indicate relevant inconsistencies between subgroups.

In addition, country effects were further evaluated. The p-value for the treatment by country interaction was 0.871. For the primary and main secondary endpoint (time to first moderate/severe exacerbation, change from baseline in pre-dose morning FEV1 and SGRQ total score over the entire treatment period), none of the countries  dominated  the  results;  neither  with  regard  to  sample  size  nor  treatment  effect. Confidence intervals are largely overlapping and point estimates per country favour TRYDONIS / RIARIFY in most cases.

Although the optimum cut-off for blood eosinophils still is a matter of debate, not surprisingly, stratified analyses  suggest  that  the  magnitude  of  the  treatment  effect  with  the  triple  combination  is  greater  in patients with higher blood eosinophil levels of ≥2%. The same trend in favour of TRYDONIS / RIARIFY was  seen  when  analysing  moderate  and  severe  exacerbations  separately.  But  as  the  study  was  not adequately  powered  to  demonstrate  a  significant  between-group  difference,  only  a  numerically  lower adjusted exacerbation rate per patient per year was reported for the TRYDONIS / RIARIFY group.

Treatment with TRYDONIS / RIARIFY was favoured by patient-reported outcomes, i.e. the St George's Respiratory Questionnaire (SGRQ) total score. Improvement in mean SGRQ total score was significantly better  with  TRYDONIS  /  RIARIFY  than  with  IND/GLY.  In  the  responder  analyses,  a  numerically  higher proportion of patients responded to TRYDONIS / RIARIFY than to IND/GLY in terms of FEV1 and SGRQ total  score  change  from  baseline  at  both  Week  52,  although  the  odds  ratios  were  not  statistically significant.  Though  the  MCID  for  the  SGRQ  total  score  is  reported  to  be ≥4 units,  an  adjusted  mean change from baseline over the 52 week treatment period of 3.2 and an adjusted mean between group difference of 1.7 may be considered to be indicative of patient benefit.

## Supportive study TRIPLE 7

The open-label design and the short(er) treatment duration of 26 weeks limit efficacy evaluations.

The  total  SGRQ  score  used  as  a  primary  efficacy  variable  in  this  study  is  a  generally  accepted  tool / questionnaire in order to measure the health status in COPD patients.

The non-inferiority margin of 4 units was not sufficiently justified and considered only clinical judgement, but  not  statistical  reasoning  as  laid  down  as  a  requirement  in  the  respective  EMA  guidance  document

<div style=\"page-break-after: always\"></div>

(EMEA/CPMP/EWP/2158/99  dated  27  July  2005).  In  addition  to  providing  assurance  that  TRYDONIS  / RIARIFY is not substantially inferior to the reference product, the chosen non-inferiority limit should be calculated or defined such that superiority over placebo is not left in doubt in such a two-arm trial (with no placebo reference). By pre-defining the MCID of 4 units (i.e. the smallest difference in the SGRQ score which patients perceive as beneficial) as the non-inferiority margin, it is no more guaranteed that this latter  requirement  is  met.  Thus,  a  more  conservative  approach  for  defining  the  non-inferiority  margin should have been chosen by the MAH. This reflects the limitations of the data of the Triple 7 study in addition to the short direction of the study.

## 2.4.4.  Conclusions on the clinical efficacy

The main efficacy assessment is based on data generated from a single pivotal phase 3b trial with study TRIPLE  8.  Over  52  weeks  of  treatment,  less  patients  in  group  TRYDONIS  /  RIARIFY  experienced  less moderate-to-severe exacerbations (35.7%, 433 events) as compared with IND/GB (37.5%, 485 events) (ITT population). The resulting adjusted rate ratio was 0.848 (p=0.043, 95% CI [0.723, 0.995]), thereby formally confirming a statistical significance. Results of the PP population confirmed the estimated effect size, but barely missed statistical significance (p=0.050, upper limit of 95% CI=1.000). Also, results of the additional analyses support the consistently borderline results for the primary endpoint. Depending on the analysis, results are either non-significant or borderline significant. Furthermore, since a treatment policy estimand is of higher relevance than a hypothetical one, an analysis based on reference data (CR or  J2R)  would  have  been  the  preferred  option  from  a  regulatory  point  of  view.  Both  reference-based imputation approaches failed to reach statistical significance.

The rate of moderate-to-severe COPD exacerbations over 52 weeks was lower with TRYDONIS / RIARIFY than with IND/GB, with a rate ratio of 0.848 (95% CI [0.723, 0.995], p-value=0.043) indicating a 15% reduction in the exacerbation rate. However, it should be stressed that this difference, in absolute terms (an estimated reduction in 0.09 exacerbations per patient per year, from 0.594 with LABA/LAMA to 0.504 with the triple therapy), is considered modest from a clinical perspective.

In addition, several other issues emerged during the assessment of the submitted documentation which in this context may challenge the internal validity of the study and data reliability. These include but are not limited to the following:

- Erroneous  subject-level  data  were  included  in  the  locked  study  database  of  the  pivotal  study TRIPLE 8, making it necessary to modify the composition of the per-protocol population after unblinding.
- Though apparently being of minor impact and not affecting the primary response variable, there was a lack of transparency by omitting information on this relevant incident in the CSR and claiming that both populations to be used in the analysis were defined prior to database lock and unblinding.

· Reportedly,  annual  audit  plans  /  programmes  were  finalised  with  significant  delay  and  for  the pivotal study TRIPLE 8, only a single site audit was performed that followed a proactive and risk-based approach.  Two  others  were  performed  in  a  reactive  manner  subsequent  to  the  announcement  of  a (routine) health authority inspection.

Nevertheless,  triple  therapy  is  currently  thought  to  be  best  used  as  an  escalation  therapy  for  those incompletely controlled with dual therapy, either ICS/LABA or LABA/LAMA (GOLD 2018) and superiority (although marginal statistically significant) of the triple combination over the dual components has been demonstrated.

<div style=\"page-break-after: always\"></div>

## 2.5.  Clinical safety

## Introduction

This  section  focuses  on  safety  data  as  generated  in  the  pivotal  study  TRIPLE  8  in  order  to  assess  the potential (negative) effects if an inhaled corticosteroid is added to dual treatment with bronchodilators in patients with advanced COPD. These results are considered to be more important than those obtained in study TRIPLE 7 because of the longer treatment duration (52 weeks vs. 26 weeks) and the study design (double-blind, double-dummy vs. open label). In addition, results of the integrated safety analysis as now provided by the applicant by pooling data from trials TRIPLE 5, TRIPLE 6, TRIPLE 7 and TRIPLE 8 are discussed. This analysis was performed for TEAEs only which were at least possibly related to treatment with TRYDONIS / RIARIFY.

## Patient exposure

In study TRIPLE 8, exposure to randomised study treatment shows the expected skewed and left-tailed distribution. Overall, the duration of study treatment was as planned per protocol and the proportion of patients  prematurely  discontinuing  the  trial  was  low  and  comparable  between  groups.  Accordingly, median treatment duration was 365 days in both groups (Table 18).

About 88.7% and 85.4% of patients received at least 48 weeks of study treatment in groups TRYDONIS / RIARIFY and IND/GB, respectively.

Table 18: Exposure to randomised treatment (safety = ITT population)

|                         | CHF 5993pMDI (N=764)   | Indacaterol/glycopyrronium bromide (N=768)   |
|-------------------------|------------------------|----------------------------------------------|
| Exposure (days)         |                        |                                              |
| n                       | 764                    | 768                                          |
| Mean (SD)               | 342.4 (70.8)           | 335.2 (81.2)                                 |
| Median                  | 365.0                  | 365.0                                        |
| Min, Max                | 6, 406                 | 3，392                                        |
| Exposure (weeks）(n (%)) |                        |                                              |
| [0-4)                   | (1.0)                  | 6 (1.2)                                      |
| [4-8)                   | (0.9)                  | 7 (0.9)                                      |
| [8-12)                  | 6 (0.8)                | 10 (1.3)                                     |
| [12-16)                 | 6 (0.8)                | 19 (2.5)                                     |
| [16-20)                 | 6 (0.8)                | 7 (0.9)                                      |
| [20-24)                 | 6(0.8)                 | 10 (1.3)                                     |
| [24-28)                 | 15 (2.0)               | 9 (1.2)                                      |
| [28-32)                 | 7 (0.9)                | 6 (0.8)                                      |
| [32-36)                 | 4 (0.5)                | 7 (0.9)                                      |
| [36-40)                 | 7 (0.9)                | 7 (0.9)                                      |
| [40-44)                 | 8 (1.0)                | 12 (1.6)                                     |
| [44-48)                 | 6 (0.8)                | 9 (1.2)                                      |
| [48-52)                 | 159 (20.8)             | 148 (19.3)                                   |
| >=52                    | 519 (67.9)             | 508 (66.1)                                   |

Source Data: Listing 16.2.5.3

Notes:

[1] Where indicated,table presents number and percentage of patients (n ()).

[2]

[3] Extent of Exposure (Days) = Date of last randomised study medication intake - Date of first randomised study medication intake + 1

In  study  TRIPLE  7,  the  majority  of  patients  completed  at  least  26  weeks  of  treatment  as  planned  per protocol  with  only  33  (5.7%)  patients  in  the  BDP/FF/GB  group  and  30  (5.2%)  patients  in  the Fluticasone/Vilanterol  +  Tiotropium  group  discontinuing  the  study.  The  mean  extent  of  exposure  was comparable in the TRYDONIS / RIARIFY and Fluticasone/Vilanterol + Tiotropium groups (178.3 and 179.3 days, respectively).

## Adverse events

Overall summary of treatment-emergent Adverse Events (TEAE)

<div style=\"page-break-after: always\"></div>

## Study TRIPLE 8

With TRYDONIS / RIARIFY, 490 (64.1%) patients experienced 1292 TEAEs: 117 (15.3%) patients were reported with 170 serious TEAEs, 43 (5.6%) patients with 50 ADRs and 1 (0.1%) patient with 1 serious ADR (Table 18). A total of 86 (11.3%) patients were reported with 129 severe TEAEs and 45 TEAEs led to study medication discontinuation in 37 (4.8%) patients. With IND/GB, 516 (67.2%) patients experienced 1432 TEAEs: 130 (16.9%) patients were reported with 208 serious TEAEs, 37 (4.8%) patients with 53 ADRs and 1 (0.1%) patient with 1 serious ADR. A total of 87 (11.3%) patients were reported with 136 severe TEAEs and 56 TEAEs led to study medication discontinuation in 47 (6.1%) patients. There were 20 TEAEs that led to death in 16 (2.1%) patients with TRYDONIS / RIARIFY and 26 TEAEs that led to death in 21 (2.7%) patients with IND/GB. None of the deaths were considered related to study treatment. Most of  the  fatal  TEAEs  were  from  the  SOCs  'cardiac  disorders'  (11  TEAEs  in  10  patients)  and  'general disorders  and  administration  site  conditions'  (11  TEAEs  in  11  patients).  COPD  exacerbation  led  to  the death of 2 patients (0.3%) in each treatment group.

Table 19: Summary of TEAEs and ADRs (safety = ITT population)

|                                                  | CHF 5993 pMDI N=764    | CHF 5993 pMDI N=764   | Indacaterol/GB N=768   | Indacaterol/GB N=768   |
|--------------------------------------------------|------------------------|-----------------------|------------------------|------------------------|
|                                                  | Number of patients (%) | Number of events      | Number of patients (%) | Number of events       |
| TEAEs                                            | 490 (64.1)             | 1292                  | 516 (67.2)             | 1432                   |
| Serious TEAEs                                    | 117 (15.3)             | 170                   | 130 (16.9)             | 208                    |
| Non-serious TEAEs                                | 453 (59.3)             | 1122                  | 471 (61.3)             | 1224                   |
| Treatment-emergent ADRs                          | 43 (5.6)               | 50                    | 37 (4.8)               | 53                     |
| Serious treatment-emergent ADRs                  | 1 (0.1)                | 1                     | 1 (0.1)                | 1                      |
| Severe TEAEs                                     | 86 (11.3)              | 129                   | 87 (11.3)              | 136                    |
| TEAEs leading to study treatment discontinuation | 37 (4.8)               | 45                    | 47 (6.1)               | 56                     |
| TEAEsleading todeatha                            | 16 (2.1)               | 20                    | 21 (2.7)               | 26                     |

ADR = Adverse drug reaction; GB = Glycopyrronium bromide; pMDI = Pressurised metered dose inhaler; TEAE = Treatmentemergent adverse event.

N = Number of patients in the Safety population.

a Patient #032821002 and Patient #616803031 had AEs leading to death and were recorded as discontinued due to AEs.

## Study TRIPLE 7

With  TRYDONIS  /  RIARIFY,  255  (44.1%)  patients  experienced  530  TEAEs:  39  (6.7%)  patients  were reported with 63 serious TEAEs, 18 (3.1%) patients with 23 ADRs and no patients were reported with serious ADRs (Table 24). A total of 26 (4.5%) patients were reported with 42 severe TEAEs and 12 TEAEs led to study medication discontinuation in 11 (1.9%) patients. With Fluticasone/Vilanterol + Tiotropium, 246 (42.5%) patients experienced 491 TEAEs: 56 (9.7%) patients were reported with 87 serious TEAEs, 22 (3.8%) patients with 30 ADRs and no patients were reported with serious ADRs. A total of 32 (5.5%) patients were reported with 44 severe TEAEs and 14 TEAEs led to study medication discontinuation in 13 (2.2%) patients. There were 3 TEAEs that led to death in 3 (0.5%) patients with TRYDONIS / RIARIFY and 6 TEAEs that led to death in 5 (0.9%) patients with Fluticasone/Vilanterol + Tiotropium.

## Common AE and ADR

## Study TRIPLE 8

TEAEs reported in ≥1% of patients and listed by preferred term (PT) are presented in Table 20.

<div style=\"page-break-after: always\"></div>

Table 20: Summary of TEAEs reported in ≥ 1% of patients by PT (safety = ITT population)

| PT                                | CHF 5993 pMDI N=764    | CHF 5993 pMDI N=764   | Indacaterol/GB N=768   | Indacaterol/GB N=768   |
|-----------------------------------|------------------------|-----------------------|------------------------|------------------------|
| PT                                | Number of patients (%) | Number of events      | Number of patients (%) | Number of events       |
| At least one TEAE                 | 490 (64.1)             | 1292                  | 516 (67.2)             | 1432                   |
| COPD*                             | 273 (35.7)             | 444                   | 288 (37.5)             | 501                    |
| Nasopharyngitis                   | 43 (5.6)               | 56                    | 37 (4.8)               | 41                     |
| Headache                          | 44 (5.8)               | 50                    | 35 (4.6)               | 39                     |
| Pneumoniab                        | 28 (3.7)c              | 32                    | 27 (3.5)d              | 29d                    |
| Back pain                         | 21 (2.7)               | 21                    | 23 (3.0)               | 27                     |
| Dyspnoea                          | 21 (2.7)               | 25                    | 21 (2.7)               | 23                     |
| Hypertension                      | 15 (2.0)               | 16                    | 22 (2.9)               | 24                     |
| Cough                             | 13 (1.7)               | 14                    | 21 (2.7)               | 25                     |
| Upper respiratory tract infection | 11 (1.4)               | 11                    | 11 (1.4)               | 11                     |
| Arthralgia                        | 10 (1.3)               | 16                    | 11 (1.4)               | 11                     |
| Rhinitis                          | 7 (0.9)                | 8                     | 13 (1.7)               | 13                     |
| Viral infection                   | 12 (1.6)               | 13                    | 7 (0.9)                | 7                      |
| Oral candidiasis                  | 13 (1.7)               | 15                    | 5 (0.7)                | 5                      |
| Respiratory tract infection viral | 9 (1.2)                | 10                    | 9 (1.2)                | 10                     |
| Toothache                         | 5 (0.7)                | 5                     | 13 (1.7)               | 13                     |
| Cardiac failure                   | 9 (1.2)                | 9                     | 7 (0.9)                | 7                      |
| Diabetes mellitus                 | 6 (0.8)                | 6                     | 10 (1.3)               | 10                     |
| Diarrhoea                         | 8 (1.0)                | 8                     | 8 (1.0)                | 8                      |
| Atrial fibrillation               | 5 (0.7)                | 7                     | 10 (1.3)               | 11                     |
| Bronchitis                        | 9 (1.2)                | 9                     | 6 (0.8)                | 6                      |
| Influenza                         | 8 (1.0)                | 9                     | 6 (0.8)                | 6                      |
| Abdominal distension              | 8 (1.0)                | 8                     | 5 (0.7)                | 6                      |
| Pain in extremity                 | 1 (0.1)                | 1                     | 10 (1.3)               | 13                     |

COPD = Chronic obstructive pulmonary disease; GB = Glycopyrronium bromide; pMDI = Pressurised metered dose inhaler; PT

= Preferred term; TEAE = Treatment-emergent adverse event.

N = Number of patients in the Safety population.

a COPD is the PT for the reported \"COPD exacerbation\".

b Pneumonia, as reported by the Investigators, includes the PTs of bronchopneumonia, interstitial lung disease, lobar pneumonia, pneumonia, pneumonia bacterial, pneumonia streptococcal, pneumonia viral and pulmonary tuberculosis.

c Patient #616806004 was reported with two events of pneumonia (PTs of pneumonia and bronchopneumonia) during treatment with CHF 5993 pMDI, so the patient was only counted once for the total number of patients with pneumonia (Listing 16.2.7.9).

d Patient #348801005 was reported with suspicion of lung tuberculosis (PT pulmonary tuberculosis) during treatment with indacaterol/GB, but pneumonia was not confirmed by the Investigator, and the patient was not counted for total pneumonias

## Study TRIPLE 7

The most common TEAE was COPD exacerbation, reported in 122 (21.1%) and 108 (18.7%) patients with TRYDONIS  /  RIARIFY  and  Fluticasone/Vilanterol  +  Tiotropium,  respectively.  Other  common  TEAEs (reported  in ≥ 2%  patients)  were  nasopharyngitis,  headache,  pneumonia  (PTs  of  bronchopneumonia, lobar pneumonia, pneumonia and pneumonia staphylococcal), respiratory tract infection viral, dyspnoea and oral candidiasis. The majority of these TEAEs were mild or moderate in intensity and resolved by the end of the study.

Integrated  Analysis  of  Treatment-Emergent  Adverse  Drug  Reactions  for  Studies  TRIPLE  5, TRIPLE 6, TRIPLE 7 and TRIPLE 8

<div style=\"page-break-after: always\"></div>

Table 21 presents all treatment-emergent ADRs with TRYDONIS / RIARIFY pooled from studies TRIPLE 5, TRIPLE 6, TRIPLE 7 and TRIPLE 8 in decreasing order of frequency by SOC and PT in the overall Safety population.  The  only  SOC  reported  in ≥ 1%  of  patients  with  BDP/FF/GB  was  the  Infections  and Infestations SOC.

## Table 21: All treatment-emergent ADRs by SOC and PT, Safety population - Studies Triple 5, Triple 6, Triple 7 and Triple 8 (integrated analysis)

<div style=\"page-break-after: always\"></div>

| SOC,PT                                          | BDP/FF/GB 400/24/50 μg N=3106   | BDP/FF/GB 400/24/50 μg N=3106   |
|-------------------------------------------------|---------------------------------|---------------------------------|
| SOC,PT                                          | Number of events                | Number of patients (%)          |
| At least l treatment-emergent ADR               | 138                             | 112 (3.6)                       |
| Infections andinfestations                      | 44                              | 37 (1.2)                        |
| Oral candidiasis                                | 31                              | 26 (0.8)                        |
| Oralfungal infection                            | 5                               | 4 (0.1)                         |
| Oropharyngeal candidiasis                       | 2                               | 2 (0.1)                         |
| Furuncle                                        | 1                               | 1 (0.0)                         |
| Laryngitis                                      | 1                               | 1 (0.0)                         |
| Lower respiratory tract infection fungal        | 1                               | 1 (0.0)                         |
| Pharyngitis                                     | 1                               | 1 (0.0)                         |
| Pneumonia                                       | 1                               | 1 (0.0)                         |
| Respiratory tract infection                     | 1                               | 1 (0.0)                         |
| Gastrointestinal disorder's                     | 21                              | 19 (0.0)                        |
| Dry mouth                                       | 15                              | 14 (0.5)                        |
| Stomatitis                                      | 3                               | 3 (0.1)                         |
| Nausea                                          | 2                               | 2 (0.1)                         |
| Aphthous stomatitis                             | 1                               | 1 (0.0)                         |
| Respiratory,thoracic and mediastinal disorder's | 17                              | 17 (0.5)                        |
| Dysphonia                                       | 8                               | 8 (0.3)                         |
| Cough                                           | 3                               | 3 (0.1)                         |
| Throat irritation                               | 2                               | 2 (0.1)                         |
| Dry throat                                      | 1                               | 1 (0.0)                         |
| Oropharyngeal pain                              | 1                               | 1 (0.0)                         |
| Pharyngeal erythema                             | 1                               | 1 (0.0)                         |
| Pharyngeal inflammation                         | 1                               | 1 (0.0)                         |
| Musculoskeletal andconnectivetissuedisorder's   | 17                              | 14 (0.5)                        |
| Muscle spasms                                   | 16                              | 14 (0.5)                        |
| Myalgia                                         | 1                               | 1 (0.0)                         |
| Cardiac disorder's                              | 8                               | 7 (0.2)                         |
| Atrial fibrillation                             | 2                               | 2 (0.1)                         |
| Angina unstable                                 | 1                               | 1 (0.0)                         |
| Atrioventricular block first degree             | 1                               | 1 (0.0)                         |
| Nodal rhythm                                    | 1                               | 1 (0.0)                         |
| Palpitations                                    | 1                               | 1 (0.0)                         |
| Sinus bradycardia                               | 1                               | 1 (0.0)                         |
| Tachycardia                                     | 1                               | 1 (0.0)                         |
| Skin and subcutaneous tissue disorder's         | 6                               | 6 (0.2)                         |
| Alopecia                                        | 2                               | 2 (0.1)                         |
| Pruritus                                        | 2                               | 2 (0.1)                         |
| Hyperkeratosis                                  | 1                               | 1 (0.0)                         |
| Papule                                          | 1                               | 1 (0.0)                         |
| Vascular disorder's                             | 6                               | 6 (0.2)                         |
| Hypertension                                    | 5                               | 5 (0.2)                         |
| Extravasationblood                              | 1                               | 1 (0.0)                         |
| Nervous system disorder's                       | 5                               | 5 (0.2)                         |
| Headache                                        | 2 1                             | 2 (0.1) 1 (0.0)                 |
| Dizziness                                       |                                 |                                 |

<div style=\"page-break-after: always\"></div>

| SOC,PT                                           | BDP/FF/GB 400/24/50 μug N=3106   | BDP/FF/GB 400/24/50 μug N=3106   |
|--------------------------------------------------|----------------------------------|----------------------------------|
| SOC,PT                                           | Number of events                 | Number of patients (%)           |
| Hypersomnia                                      | 1                                | 1 (0.0)                          |
| Tremor                                           | 1                                | 1 (0.0)                          |
| Investigations                                   | 4                                | 4 (0.1)                          |
| Electrocardiogram QT prolonged                   | 2                                | 2 (0.1)                          |
| Electrocardiogram PR prolongation                | 1                                | 1 (0.0)                          |
| Hepatic enzyme increased                         | 1                                | 1 (0.0)                          |
| Metabolism and nutrition disorder's              | 3                                | 3 (0.1)                          |
| Decreased appetite                               | 1                                | 1 (0.0)                          |
| Diabetes mellitus                                | 1                                | 1 (0.0)                          |
| Hypokalaemia                                     | 1                                | 1 (0.0)                          |
| Psychiatric disorders                            | 2                                | 2 (0.1)                          |
| Anxiety                                          | 1                                | 1 (0.0)                          |
| Insomnia                                         | 1                                | 1 (0.0)                          |
| Renal andurinarydisorder's                       | 2                                | 2 (0.1)                          |
| Dysuria                                          | 1                                | 1 (0.0)                          |
| Urinary retention                                | 1                                | 1 (0.0)                          |
| Generaldisorder'sandadministrationsiteconditions | 1                                | 1 (0.0)                          |
| Asthenia                                         | 1                                | 1 (0.0)                          |
| Immune system disorder's                         | 1                                | 1 (0.0)                          |
| Hypersensitivity                                 | 1                                | 1 (0.0)                          |
| Reproductive system and breast disorder's        | 1                                | 1 (0.0)                          |
| Benign prostatic hyperplasia                     | 1                                | 1 (0.0)                          |

CSR study Triple 8 Listing 16.2.7.4.

Note: treatment doses = total daily doses.

## Serious adverse event/deaths/other significant events

## Deaths

In study TRIPLE 8, there were 20 TEAEs leading to death reported in 16 (2.1%) patients with TRYDONIS / RIARIFY and 26 TEAEs leading to death reported in 21 (2.7%) patients with IND/GB (Table 22). The most common TEAEs leading to death were from the General Disorders and Administration Site Conditions and Cardiac  Disorders  SOCs.  In  both  SOCs  the  frequency  of  events  was  lower  with  BFP/FF/GB  than  with IND/GB. Of note, COPD exacerbation led to death in 2 (0.3%) patients in each treatment group. None of the deaths were considered related to study treatment.

Table 22: All TEAEs leading to death by SOC and PT, Safety population - Study Triple 8

<div style=\"page-break-after: always\"></div>

| SOC,PT                                                              | BDP/FF/GB 400/24/50 μg N=764   | BDP/FF/GB 400/24/50 μg N=764   | Indacaterol/GB 85/43 μg N=768   | Indacaterol/GB 85/43 μg N=768   |
|---------------------------------------------------------------------|--------------------------------|--------------------------------|---------------------------------|---------------------------------|
| SOC,PT                                                              | Number of events               | Number of patients (%)         | Number of events                | Number of patients (%)          |
| AtleastlTEAEleadingtodeath                                          | 20                             | 16 (2.1)                       | 26                              | 21 (2.7)                        |
| General disorder'sand administration site conditions                | 3                              | 3 (0.4)                        | 8                               | 8 (1.0)                         |
| Death                                                               | 2                              | 2 (0.3)                        | 3                               | 3 (0.4)                         |
| Sudden cardiac death                                                | 0                              | 0 (0.0)                        | 3                               | 3 (0.4)                         |
| Sudden death                                                        | 1                              | 1 (0.1)                        | 2                               | 2 (0.3)                         |
| Cardiac disorder's                                                  | 2                              | 2 (0.3)                        | 9                               | 8 (1.0)                         |
| Acutemyocardial infarction                                          | 0                              | 0 (0.0)                        | 4                               | 4 (0.5)                         |
| Atrial fibrillation                                                 | 0                              | 0 (0.0)                        | 2                               | 2 (0.3)                         |
| Cardio-respiratory arrest                                           | 1                              | 1 (0.1)                        | 1                               | 1 (0.1)                         |
| Arrhythmia                                                          | 0                              | 0 (0.0)                        | 1                               | 1 (0.1)                         |
| Cardiopulmonary failure                                             | 1                              | 1 (0.1)                        | 0                               | 0 (0.0)                         |
| Left ventricularfailure                                             | 0                              | 0 (0.0)                        | 1                               | 1 (0.1)                         |
| Respiratory, thoracic and mediastinal disorders                     | 5                              | 4 (0.5)                        | 5                               | 4 (0.5)                         |
| COPDa                                                               | 2                              | 2 (0.3)                        | 2                               | 2 (0.3)                         |
| Pulmonary embolism                                                  | 0                              | 0                              | 2                               | 2 (0.3)                         |
| Acute respiratory distress syndrome                                 | 1                              | 1 (0.1)                        | 0                               | 0 (0.0)                         |
| Acute respiratory failure                                           | 1                              | 1 (0.1)                        | 0                               | 0 (0.0)                         |
| Respiratory distress                                                | 1                              | 1 (0.1)                        | 0                               | 0 (0.0)                         |
| Respiratory failure                                                 | 0                              | 0 (0.0)                        | 1                               | 1 (0.1)                         |
| Infections and infestations                                         | 2                              | 2 (0.3)                        | 2                               | 2 (0.3)                         |
| Pneumonia                                                           | 2                              | 2 (0.3)                        | 1                               | 1 (0.1)                         |
| Pneumonia                                                           | 2                              | 2 (0.3)                        | 0                               | 0 (0.0)                         |
| Pulmonarytuberculosis                                               | 0                              | 0 (0.0)                        | 1                               | 1 (0.1)                         |
| Necrotising fasciitis                                               | 0                              | 0 (0.0)                        | 1                               | 1 (0.1)                         |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 4                              | 4 (0.5)                        | 0                               | 0 (0.0)                         |
| Lung neoplasm malignant                                             | 2                              | 2 (0.3)                        | 0                               | 0 (0.0)                         |
| Bladder transitional cell carcinoma                                 | 1                              | 1 (0.1)                        | 0                               | 0 (0.0)                         |
| Oesophageal carcinoma                                               | 1                              | 1 (0.1)                        | 0                               | 0 (0.0)                         |
| Injury, poisoning and procedural complications                      | 2                              | 2 (0.3)                        | 1                               | 1 (0.1)                         |
| Multiple injuries                                                   | 1                              | 1 (0.1)                        | 1                               | 1 (0.1)                         |
| Post procedural complication                                        | 1                              | 1 (0.1)                        | 0                               | 0 (0.0)                         |
| Ner'voussystem disorder's                                           | 1                              | 1 (0.1)                        |                                 | 1 (0.1)                         |
| Cerebrovascular accident                                            | 1                              | 1 (0.1)                        | 1                               | 1 (0.1)                         |
| Vasculardisorder's                                                  | 1                              | 1 (0.1)                        | 0                               | 0 (0.0)                         |
| Circulatory collapse                                                | 1                              | 1 (0.1)                        | 0                               | 0 (0.0)                         |

In study TRIPLE 7, there were 3 TEAEs leading to death reported in 3 (0.5%) patients with TRYDONIS / RIARIFY  and  6  TEAEs  leading  to  death  reported  in  5  (0.9%)  patients  with  Fluticasone/Vilanterol  + Tiotropium. The only TEAE leading to death reported in ≥ 2 patients in either treatment group was COPD exacerbation, which led to death in 2 (0.3%) patients in the Fluticasone/Vilanterol + Tiotropium group. None of the deaths were considered related to study treatment.

## Other Serious Adverse Events

In study TRIPLE 8, 170 serious TEAEs were reported in 117 (15.3%) patients with TRYDONIS / RIARIFY and  208  serious  TEAEs  were  reported  in  130  (16.9%)  patients  with  IND/GB.  The  incidence  of  serious TEAEs  reported  in ≥ 2  patients  by  PT  in  either  treatment  group  is  presented  in  decreasing  order  of frequency in Table 23.

<div style=\"page-break-after: always\"></div>

Table 23: Serious TEAEs reported in ≥ 2 patients by PT, Safety population -Study Triple 8

<!-- image -->

| PT                                | BDP/FF/GB 400/24/50 g N=764   | BDP/FF/GB 400/24/50 g N=764   | Indacaterol/GB 85/43 μg N=768   | Indacaterol/GB 85/43 μg N=768   |
|-----------------------------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------|
| PT                                | Number of events              | Number of patients (%)        | Number of events                | Number of patients (%)          |
| At least l serious TEAE           | 170                           | 117 (15.3)                    | 208                             | 130 (16.9)                      |
| COPDa                             | 75                            | 61 (8.0)                      | 94                              | 69 (9.0)                        |
| Pneumonia                         | 18                            | 18 (2.4)                      | 18                              | 17 (2.2)                        |
| Bronchopneumonia                  | 0                             | 0 (0.0)                       | 2                               | 2 (0.3)                         |
| Lobar pneumonia                   | 1                             | 1 (0.1)                       | 3                               | 2 (0.3)                         |
| Pneumonia                         | 16                            | 16 (2.1)                      | 10                              | 10 (1.3)                        |
| Pneumoniabacterial                | 1                             | 1 (0.1)                       | 0                               | 0 (0.0)                         |
| Pneumoniastreptococcal            | 0                             | 0 (0.0)                       | 1                               | 1 (0.1)                         |
| Pneumoniaviral                    | 0                             | 0 (0.0)                       | 1                               | 1 (0.1)                         |
| Pulmonarytuberculosis             | 0                             | 0 (0.0)                       | 1                               | 1 (0.1)                         |
| Acute myocardial infarction       | 0                             | 0 (0.0)                       | 5                               | 5 (0.7)                         |
| Atrial fibrillation               | 0                             | 0 (0.0)                       | 5                               | 5 (0.7)                         |
| Death                             | 2                             | 2 (0.3)                       | 3                               | 3 (0.4)                         |
| Lungneoplasmmalignant             | 4                             | 4 (0.5)                       | 1                               | 1 (0.1)                         |
| Cardiopulmonaryfailure            | 2                             | 2 (0.3)                       | 2                               | 2 (0.3)                         |
| Pulmonary embolism                | 2                             | 2 (0.3)                       | 2                               | 2 (0.3)                         |
| Myocardial infarction             | 1                             | 1 (0.1)                       | 3                               | 3 (0.4)                         |
| Respiratory failure               | 1                             | 1 (0.1)                       | 3                               | 3 (0.4)                         |
| Atrial flutter                    | 0                             | 0 (0.0)                       | 3                               | 3 (0.4)                         |
| Sudden cardiac death              | 0                             | 0 (0.0)                       | 3                               | 3 (0.4)                         |
| Bronchiectasis                    | 1                             | 1 (0.1)                       | 2                               | 2 (0.3)                         |
| Lung adenocarcinoma               | 1                             | 1 (0.1)                       | 2                               | 2 (0.3)                         |
| Sudden death                      | 1                             | 1 (0.1)                       | 2                               | 2 (0.3)                         |
| Acuterespiratory failure          | 2                             | 2 (0.3)                       | 0                               | 0 (0.0)                         |
| Bladdertransitional cellcarcinoma | 2                             | 2 (0.3)                       | 0                               | 0 (0.0)                         |
| Cerebral ischaemia                | 2                             | 2 (0.3)                       | 0                               | 0 (0.0)                         |
| Retinal detachment                | 2                             | 2 (0.3)                       | 0                               | 0 (0.0)                         |
| Renal failure                     | 0                             | 0 (0.0)                       | 2                               | 2 (0.3)                         |

The  majority  of  serious  TEAEs  by  PT  were  reported  in ≤ 2  patients  in  either  treatment  group.  Those reported  in  &gt;  2  patients  were  COPD  exacerbation,  pneumonia,  acute  myocardial  infarction,  atrial fibrillation,  death,  lung  neoplasm  malignant,  myocardial  infarction,  respiratory  failure,  atrial  flutter  and sudden cardiac death. Only 1 serious TEAE in each group was assessed as related to study treatment: 1 event of dysuria in the BDP/FF/GB group, which led to study treatment interruption and was resolved before study discontinuation due to withdrawal of consent, and 1 event of atrial fibrillation in the IND/GB group, which did not lead to study treatment modification and was not resolved before study participation ended.

In study TRIPLE 7, 63 serious TEAEs were reported in 39 (6.7%) patients with TRYDONIS / RIARIFY and 87 serious TEAEs were reported in 56 (9.7%) patients with Fluticasone/Vilanterol + Tiotropium.

The  majority  of  serious  TEAEs  by  PT  were  reported  in ≤ 2  patients  in  either  treatment  group.  Those reported in &gt; 2 patients were COPD exacerbation, pneumonia (PTs of lobar pneumonia, pneumonia and pneumonia staphylococcal) and respiratory failure.

## Other Significant Adverse Events - pneumonia

## Study TRIPLE 8

There were 32 events of treatment-emergent pneumonia (including PTs of bronchopneumonia, interstitial lung disease, lobar pneumonia, pneumonia, pneumonia bacterial, pneumonia streptococcal, pneumonia viral  and  pulmonary  tuberculosis)  reported  in  28  (3.7%)  patients  with  TRYDONIS  /  RIARIFY  and  29

<div style=\"page-break-after: always\"></div>

events reported in 27 (3.5%) patients with IND/GB. Only one confirmed event of pulmonary tuberculosis was reported in 1 (0.1%) patient with IND/GB and none with TRYDONIS / RIARIFY (Table 24).

Table 24: Treatment-emergent pneumonias and pneumonia rates (safety = ITT population)

|                                            | CHF 5993 pMDI N=764    | CHF 5993 pMDI N=764   | Indacaterol/GB N=768   | Indacaterol/GB N=768   |
|--------------------------------------------|------------------------|-----------------------|------------------------|------------------------|
|                                            | Number of patients (%) | Number of events      | Number of patients (%) | Number of events       |
| All pneumonias                             | 28 (3.7)               | β2                    | 27 (3.5)               | 29                     |
| Community acquired pneumonia               | 27 (3.5)               | 29                    | 25 (3.3)               | 26                     |
| Nosocomial pneumonia                       | 1 (0.1)                | 2                     | 1 (0.1)                | 1                      |
| Missing information                        | 1 (0.1)                | 1                     | 2 (0.3)                | 2                      |
| Lobar pneumonia                            | 11 (1.4)               | 12                    | 8 (1.0)                | 9                      |
| Bronchopneumonia                           | 13 (1.7)               | 15                    | 14 (1.8)               | 14                     |
| Interstitial pneumonia                     | 3 (0.4)                | 3                     | 4 (0.5)                | 4                      |
| Missing information                        | 2 (0.3)                | 2                     | 2 (0.3)                | 2                      |
| Total follow-up time (years)               | 718.20                 | 718.20                | 707.37                 | 707.37                 |
| Pneumonia rate per 1,000 patients per year | 44.556                 | 44.556                | 40.997                 | 40.997                 |

GB = Glycopyrronium bromide; pMDI = Pressurised metered dose inhaler.

N = Number of patients in the Safety population.

The majority of reported pneumonias were moderate in intensity and most of them resolved by the end of the  study.  A  total  of  18  serious  pneumonias  were  reported  in  18  (2.4%)  patients  with  TRYDONIS  / RIARIFY  and  18  serious  pneumonias  were  reported  in  17  (2.2%)  patients  with  IND/GB.  None  of  the serious  pneumonias  were  considered  related  to  the  study  treatment  and  1  non-serious  pneumonia  of moderate  intensity  with  BDP/FF/GB  was  considered  related  to  the  study  treatment.  Of  note,  the treatment-related event of pneumonia reported above was also assessed as possibly caused by a severe acute respiratory syndrome.

Three events of pneumonia led to study medication discontinuation in 3 (0.4%) patients with TRYDONIS / RIARIFY and 1 event in 1 (0.1%) patient with IND/GB. Of these, 2 events of pneumonia in 2 (0.3%) patients in the BDP/FF/GB group and 1 event in 1 (0.1%) patient in the IND/GB group led to death and one event of pneumonia in the BDP/FF/GB group was assessed as 'not verified' by the site and the patient died from an unknown cause.

The pneumonia rate per 1,000 patients per year was comparable with TRYDONIS / RIARIFY and IND/GB (44.6 vs. 41.0).

With both treatments, most cases were classified by investigators to be community-acquired. Only one non-serious pneumonia of moderate intensity was considered by the investigators to be related to the study treatment (one patient in TRYDONIS / RIARIFY group).

## Study TRIPLE 7

There  were  13  events  of  treatment-emergent  pneumonia  (including  PTs  of  bronchopneumonia,  lobar pneumonia, pneumonia and pneumonia staphylococcal) reported in 11 (1.9%) patients with TRYDONIS / RIARIFY  and  15  events  reported  in  15  (2.6%)  patients  with  Fluticasone/Vilanterol  +  Tiotropium.  The majority of reported pneumonias were moderate in intensity and most of them resolved by the end of the study. A total of 9 serious pneumonias were reported in 8 (1.4%) patients with TRYDONIS / RIARIFY and 11  serious  pneumonias  were  reported  in  11  (1.9%)  patients  with  Fluticasone/Vilanterol  +  Tiotropium. None were considered related to the study treatment. One event of pneumonia led to study medication

<div style=\"page-break-after: always\"></div>

discontinuation  in  1  (0.2%)  patient  and  1  event  of  pneumonia  led  to  death  in  1  (0.2%)  patient  with Fluticasone/Vilanterol + Tiotropium.

The pneumonia rate per 1,000 patients per year was slightly lower with TRYDONIS / RIARIFY (44.2) than with Fluticasone/Vilanterol + Tiotropium (50.6).

## Other Significant Adverse Events - cardiovascular safety

## Study TRIPLE 8

About 60% of patients of the safety population were reported to suffer from vascular disorders (452 patients  [59.2%]  in  TRYDONIS  /  RIARIFY  group  and  480  patients  [62.5%]  in  IND/GB  group),  with hypertension  being  the  most  frequent  PT  (54.6%  and  57.8%  of  patients,  respectively).  Pre-existing cardiac  disorders  were  reported  in  198  patients  (25.9%)  of  group  CHF  5993  pMDI  and  214  patients (27.9%) in group IND/GB.

A similar proportion  of  patients  in  TRYDONIS  /  RIARIFY  and  IND/GB  groups  experienced  any cardiovascular event (11.0% vs. 12.5%, respectively).

The most frequently reported cardiovascular events were cardiac failures, with 19 events in TRYDONIS / RIARIFY group and 18 events in IND/GB group and arrhythmias, with 20 events in TRYDONIS / RIARIFY group and 24 events in IND/GB group. Most arrhythmias were of the tachycardia-type (6 and 4 events, respectively). None of these cardiovascular events was considered related to treatment with TRYDONIS / RIARIFY.

## Laboratory findings

## Study TRIPLE 8

Overall, changes in all haematology and biochemistry parameters from screening to both Week 26 and Week  52  were  minimal  with  TRYDONIS  /  RIARIFY  and  IND/GB,  with  no  major  differences  between treatments.  CS  abnormalities  in  haematology  parameters,  which  were  associated  with  serious  TEAEs, were  reported  in  2  patients  with  TRYDONIS  /  RIARIFY  (PTs:  bladder  transitional  cell  carcinoma  and Hodgkin's  disease).  Neither  of  these  serious  TEAEs  were  considered  related  to  study  treatment.  CS abnormalities in biochemistry parameters, which were associated with serious TEAEs, were reported in 2 patients with TRYDONIS / RIARIFY (PTs: adenocarcinoma gastric and type 2 diabetes mellitus). Neither of these serious TEAEs were considered related to study treatment.

## Study TRIPLE 7

Overall,  changes  in  all  haematology  and  biochemistry  parameters  from  screening  to  Week  26  were minimal  with  TRYDONIS  /  RIARIFY  and  Fluticasone/Vilanterol  +  Tiotropium,  with  no  major  differences between treatments. For all haematology parameters, the majority of patients presented normal or NCS values  at  screening  and  Week  26.  None  of  the  CS  abnormalities  in  haematology  parameters  assessed during  the  study  were  reported  as  serious  TEAEs.  Clinically  significant  abnormalities  in  biochemistry parameters were reported as a serious TEAE (PT: hepatic enzyme increased) in 1 (0.2%) patient with TRYDONIS / RIARIFY; this TEAE was not considered related to study treatment.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

Table 25: TEAEs stratified by age group in patients treated with TRYDONIS / RIARIFY, Safety population - Studies TRIPLE 5, TRIPLE 6, TRIPLE 7 and TRIPLE 8 (integrated analysis)

| TEAEs                                                                                 | Age <65 years         | Age 65-74 years       | Age 75-84 years      | Age 85+ years    |
|---------------------------------------------------------------------------------------|-----------------------|-----------------------|----------------------|------------------|
| Total AEs                                                                             | (N=169 3) 893 (52.7%) | (N=110 5) 628 (56.8%) | (N=303 ) 183 (60.4%) | (N =5) 3 (60.0%) |
| Serious AEs - Total                                                                   | 191 (11.3%)           | 166 (15.0%)           | 45 (14.9%)           | 0 (0.0%)         |
| - Fatal                                                                               | 24 (1.4%)             | 25 (2.3%)             | 5 (1.7%)             | 0 (0.0%)         |
| - Hospitalization/prolong existing hospitalization                                    | 176 (10.4%)           | 152 (13.8%)           | 38 (12.5%)           | 0 (0.0%)         |
| - Life-threatening                                                                    | 12 (0.7%)             | 12 (1.1%)             | 4 (1.3%)             | 0 (0.0%)         |
| - Disability/incapacity                                                               | 3 (0.2%)              | 7 (0.6%)              | 3 (1.0%)             | 0 (0.0%)         |
| - Other (medically significant)                                                       | 21 (1.2%)             | 24 (2.2%)             | 10 (3.3%)            | 0 (0.0%)         |
| AEs leading to drop-out                                                               | 42 (2.5%)             | 57 (5.2%)             | 17 (5.6%)            | 0 (0.0%)         |
| Psychiatric disorders                                                                 | 18 (1.1%)             | 10 (0.9%)             | 6 (2.0%)             | 0 (0.0%)         |
| Nervous system disorders                                                              | 86 (5.1%)             | 78 (7.1%)             | 30 (9.9%)            | 1 (20.0%)        |
| Accidents and injuries                                                                | 32 (1.9%)             | 28 (2.5%)             | 5 (1.7%)             | 0 (0.0%)         |
| Cardiac disorders                                                                     | 78 (4.6%)             | 73 (6.6%)             | 20 (6.6%)            | 0 (0.0%)         |
| Vascular disorders                                                                    | 59 (3.5%)             | 60 (5.4%)             | 11 (3.6%)            | 1 (20.0%)        |
| Cerebrovascular disorders                                                             | 8 (0.5%)              | 18 (1.6%)             | 2 (0.7%)             | 0 (0.0%)         |
| Infections and infestations                                                           | 307 (18.1%)           | 212 (19.2%)           | 59 (19.5%)           | 2 (40.0%)        |
| Anticholinergic syndrome                                                              | 28 (1.7%)             | 24 (2.2%)             | 10 (3.3%)            | 0 (0.0%)         |
| Quality of life decreased (PT)                                                        | 0 (0.0%)              | 0 (0.0%)              | 0 (0.0%)             | 0 (0.0%)         |
| Quality of life decreased (selection of PTs)                                          | 44 (2.6%)             | 35 (3.2%)             | 18 (5.9%)            | 0 (0.0%)         |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures | 44 (2.6%)             | 48 (4.3%)             | 9 (3.0%)             | 0 (0.0%)         |
| Pneumonias                                                                            | 42 (2.5%)             | 38 (3.4%)             | 10 (3.3%)            | 0 (0.0%)         |

Number and percentage of patients with at least one TEAE are presented.

Source: CSR study TRIPLE 5, Listing 16.2.7.2; CSR study TRIPLE 6, Listing 16.2.7.2; CSR study TRIPLE 7, Listing 16.2.7.2; CSR study TRIPLE 8, Listing 16.2.7.2

## Safety related to drug-drug interactions and other interactions

No new drug interaction studies or information have been conducted or collected since the approval of Trydonis / Riarify.

## Discontinuation due to adverse events

In study TRIPLE 8, TEAEs leading to study medication discontinuation were reported in 37 (4.8%) and 47 (6.1%) patients with TRYDONIS / RIARIFY and IND/GB, respectively. The incidence of TEAEs leading to study medication discontinuation is presented in Table 26 when reported in ≥ 2 patients by PT in either treatment group.

<div style=\"page-break-after: always\"></div>

Table 26: TEAEs leading to study medication discontinuation reported in ≥ 2  patients by PT, Safety population - Study Triple 8

| PT                                                    | BDP/FF/GB 400/24/50 μug N=764   | BDP/FF/GB 400/24/50 μug N=764   | Indacaterol/GB 85/43 g N=768   | Indacaterol/GB 85/43 g N=768   |
|-------------------------------------------------------|---------------------------------|---------------------------------|--------------------------------|--------------------------------|
|                                                       | Number of events                | Number of patients (%)          | Number of events               | Number of patients (%)         |
| AtleastlTEAEleadingtostudy medication discontinuation | 45                              | 37 (4.8)                        | 56                             | 47 (6.1)                       |
| COPDa                                                 | 5                               | 5 (0.7)                         | 10                             | 10 (1.3)                       |
| Death                                                 | 2                               | 2 (0.3)                         | 3                              | 3 (0.4)                        |
| Acute myocardial infarction                           | 0                               | 0 (0.0)                         | 4                              | 4 (0.5)                        |
| Lung neoplasm malignant                               | 3                               | 3 (0.4)                         | 1                              | 1 (0.1)                        |
| Pneumonia                                             | 3                               | 3 (0.4)                         | 1                              | 1 (0.1)                        |
| Pneumonia                                             | 3                               | 3 (0.4)                         | 0                              | 0 (0.0)                        |
| Pulmonary tuberculosis                                | 0                               | 0 (0.0)                         | 1b                             | 1 (0.1)b                       |
| Cardiopulmonaryfailure                                | 1                               | 1 (0.1)                         | 2                              | 2 (0.3)                        |
| Sudden cardiac death                                  | 0                               | 0 (0.0)                         | 3                              | 3 (0.4)                        |
| Sudden death                                          | 1                               | 1 (0.1)                         | 2                              | 2 (0.3)                        |
| Acuterespiratoryfailure                               | 2                               | 2 (0.3)                         | 0                              | 0 (0.0)                        |
| Bladder transitional cell carcinoma                   | 2                               | 2 (0.3)                         | 0                              | 0 (0.0)                        |
| Dyspnoea                                              | 0                               | 0 (0.0)                         | 2                              | 2 (0.3)                        |
| Pulmonary embolism                                    | 0                               | 0 (0.0)                         | 2                              | 2 (0.3)                        |

The majority of TEAEs that led to study medication discontinuation by PT were reported in ≤ 2 patients in either treatment group; those reported in &gt; 2 patients were:

-  COPD exacerbation which led to study medication discontinuation of 5 (0.7%) and 10 (1.3%) patients with TRYDONIS / RIARIFY and IND/GB, respectively;
-  Death  which  led  to  study  medication  discontinuation  of  2  (0.3%)  and  3  (0.4%)  patients  with TRYDONIS / RIARIFY and IND/GB, respectively;
-  Acute myocardial infarction which led to study medication discontinuation of 4 (0.5%) patients in the IND/GB group;
-  Lung neoplasm malignant which led to study medication discontinuation of 3 (0.4%) and 1 (0.1%) patients with TRYDONIS / RIARIFY and IND/GB, respectively;
-  Pneumonia  (PTs  of pneumonia  and  pulmonary  tuberculosis) which led to study medication discontinuation  of  3  (0.4%)  and  1  (0.1%)  patients  with  TRYDONIS  /  RIARIFY  and  IND/GB, respectively;
-  Sudden  cardiac  death  which  led  to  study  medication  discontinuation  of  3  (0.4%)  patients  in  the IND/GB group.

Of  the  101  TEAEs  leading  to  study  medication  discontinuation,  5  were  assessed  to  be  related  to treatment;  2  TEAEs  in  2  patients  with  TRYDONIS  /  RIARIFY  (1  event  of  dry  cough  and  1  event  of headache)  and  3  TEAEs  in  2  patients  with  IND/GB  (1  event  of  eye  allergy,  1  event  of  itching  with exanthema and 1 event of itch on all body). All these events were mild or moderate in intensity and 1 event resolved by the end of the study (PT: cough).

In study TRIPLE 7, TEAEs leading to study medication discontinuation were reported in 11 (1.9%) and 13 (2.2%) patients with TRYDONIS / RIARIFY and Fluticasone/Vilanterol + Tiotropium, respectively.

The majority of TEAEs that led to study medication discontinuation by PT were reported in ≤ 2 patients in either treatment group; the only TEAE reported in &gt; 2 patients was COPD exacerbation which led to study medication discontinuation of 3 (0.5%) patients in each treatment group.

<div style=\"page-break-after: always\"></div>

Of the 26 TEAEs leading to study medication discontinuation, 4 were assessed to be related to treatment; 2 TEAEs in 2 patients with TRYDONIS / RIARIFY (1 event of papule and 1 event of urinary retention) and 2 TEAEs in 2 patients with Fluticasone/Vilanterol + Tiotropium (1 event of muscle spasms and 1 event of dysgeusia). All these events were mild or moderate in intensity and resolved by the end of the study.

## Post marketing experience

The  following  analysis  refers  to  spontaneous  reports  of  ADRs  collected  for  TRIMBOW  /  TRYDONIS  / RIARIFY received by the MAH and its partners in the period from 31 July 2017 (i.e. date of first launch of the product) to 31 January 2018 (the reference period).

The  patient  exposure  in  the  reference  period  was  calculated  from  the  available  sales  volumes  in  the countries where the product is marketed. Especially during the initial phase of a product to be launched in more  than  one  market,  such  sales  data  may  overestimate  the  actual  exposure  by  assuming  that  all wholesaler stocks are dispensed to patients, and also due to the fact that it does not account for patients' non-compliance with the prescribed amount of dispensed drug (e.g. 2 puffs bid). Finally, the product is currently sold in multipacks containing either 2 or 3 canisters each, thereby introducing another bias for the proper calculation.

In the reference period, a total number of 32 Individual Case Safety Reports (ICSRs, 5 serious and 27 non-serious, including spontaneous cases, literature cases, cases from regulatory authorities and cases from non-interventional studies) corresponding to 53 ADRs, were collected.

No significant safety information concerning serious and non-serious ADRs, fatal cases, drug interactions, drug abuse or misuse, experience in special patient groups or during pregnancy or lactation, or effects of long-term treatment has been reported in the post-marketing experience.

Overall, the safety profile of the product in COPD patients remains unchanged.

## 2.5.1.  Discussion on clinical safety

Focus  was  made  on  safety  data  as  generated  in  the  pivotal  study  TRIPLE  8  in  order  to  assess  the potential (negative) effects if an inhaled corticosteroid is added to dual treatment with bronchodilators in patients with advanced COPD. These results are considered to be more important than those obtained in study TRIPLE 7 because of the longer treatment duration (52 weeks vs. 26 weeks) and the study design (double-blind, double-dummy vs. open label). In addition, results of the integrated safety analysis were provided by the applicant by pooling data from trials TRIPLE 5, TRIPLE 6, TRIPLE 7 and TRIPLE 8. The integrated safety analysis was used to update SmPC Section 4.8.

The safety population supporting the extension of indication comprised a total of 764 subjects treated with the closed triple combination TRYDONIS / RIARIFY in Study TRIPLE 8. About 88.7% of those patients received  at  least  48  weeks  of  study  treatment.  Similar  to  prior  studies  patients  with  significant cardiovascular (CV) disease were excluded. Overall, the safety database is considered to be adequate for the proposed extension of indication.

The percentage of patients who have had a fatal outcome was in the range expected for this population of COPD patients.  No  consistent  between-groups  differences  or  imbalances  were  noted  for  TEAEs  having higher incidence rates. Random effects are most likely responsible for minor imbalances seen for TEAEs occurring in fewer patients.

Notable, in study TRIPLE 7, one patient had suddenly and unexpectedly died a few days only after having had an uneventful study visit 3. The case was reported by the investigator as «respiratory failure», but in this case autopsy results clearly pointed towards an acute and purulent infection of the lung as the direct cause of death. In study TRIPLE 8, another patient (#616803031) was admitted to the ICU of a remote

<div style=\"page-break-after: always\"></div>

hospital, underwent cardiopulmonary resuscitation and died two days later. The applicant stated that the event term reported by the investigator (« acute respiratory failure », coded PT: acute respiratory failure ) was not challenged, thus accepting the «primary cause of death». No compelling arguments and well-founded epicrisis were forwarded by the applicant why an (acute) infectious pulmonary event (leading to an acute coronary  syndrome)  was  excluded  this  second  patient.  Thus  and  in  conclusion,  based  on  these  two examples,  doubts  remain  on  whether  due  care  and  diligence  were  exercised  by  the  applicant  (or  its service providers) throughout trial conduct in fully assessing fatal / serious events and potential COPD exacerbations.

There were 32 events of treatment-emergent pneumonia (including PTs of bronchopneumonia, interstitial lung disease, lobar pneumonia, pneumonia, pneumonia bacterial, pneumonia streptococcal, pneumonia viral  and  pulmonary  tuberculosis)  reported  in  28  (3.7%)  patients  with  TRYDONIS  /  RIARIFY  and  29 events reported in 27 (3.5%) patients with IND/GB. Only one confirmed event of pulmonary tuberculosis was  reported  in  1  (0.1%)  patient  with  IND/GB  and  none  with  TRYDONIS  /  RIARIFY.  The  majority  of reported pneumonias were moderate in intensity and most of them resolved by the end of the study. A total of 18 serious pneumonias were reported in 18 (2.4%) patients with TRYDONIS / RIARIFY and 18 serious pneumonias were reported in 17 (2.2%) patients with IND/GB. None of the serious pneumonias were considered related to the study treatment and 1 non-serious pneumonia of moderate intensity with TRYDONIS / RIARIFY was considered related to the study treatment.

ICS-containing treatments are known to increase the risk of pneumonia in COPD patients. This signal was first reported in a large clinical trial of 3 years treatment duration, comparing a fluticasone propionate/salmeterol combination with its component parts and placebo (TORCH study, Calverley et al 2007 ). Based on its results, the CHMP Pharmacovigilance Working Party concluded in 2010 that treatment with an ICS, either alone or in combination with a LABA, increases the risk of pneumonia in patients with COPD.

On 27 April 2015, the European Commission triggered a referral under Article 31 of Directive 2001/83/EC. The PRAC review confirms that COPD patients treated with inhaled corticosteroids are at increased risk of pneumonia;  however  the  Committee's  view  is  that  the  benefits  of  inhaled  corticosteroids  continue  to outweigh their risks. The PRAC also looked whether there were any differences in the risk of pneumonia between these products, and did not find conclusive evidence of such difference. In addition, update of the  product  information  including  a  specific  warning  in  SmPC  Section  4.4  was  requested  for  all  ICS containing products with a COPD indication to adequately reflect the current knowledge.

The provided data on pneumonia are not suggestive of a relevantly increased risk of pneumonia when an ICS is added to double bronchodilator therapy. In study TRIPLE 8, the pneumonia event rate per 1'000 subject-years  under  triple  therapy  (44.6)  was  slightly  higher  than  those  observed  in  the  pivotal  trials endorsing the initial marketing authorisation (TRIPLE 5: 38.9; TRIPLE 6: 29.2). However, in contrast to other studies comparing ICS/LABA/LAMA (e.g. Lipson DA at al. 2018), no higher risk was observed when adding  an  ICS  to  double  bronchodilator  therapy  (IND/GB:  41.0). The  interpretation  of  these observations is somehow difficult, but most likely the sample size/statistical power of TRIPLE 8  was  not  large  enough  to  detect  a  difference  among  groups,  even  if  one  may  have  been present. Thus, at the time being no firm conclusions can be drawn given the limited nature of the data .

About  60%  of  patients  of  the  safety  population  were  reported  to  suffer  from  vascular  disorders  (452 patients  [59.2%]  in  TRYDONIS  /  RIARIFY  group  and  480  patients  [62.5%]  in  IND/GB  group),  with hypertension  being  the  most  frequent  PT  (54.6%  and  57.8%  of  patients,  respectively).  Pre-existing cardiac  disorders  were  reported  in  198  patients  (25.9%)  of  group  CHF  5993  pMDI  and  214  patients (27.9%) of group IND/GB.

<div style=\"page-break-after: always\"></div>

Note: As mentioned earlier, inclusion/ exclusion criteria excluded patients with clinically significant cardiovascular  conditions  from  study  participation.  Also,  in  contrast  to  studies  TRIPLE  5  and  TRIPLE  6,  the composite endpoint 'major adverse cardiovascular events (MACE)' was not (centrally) adjudicated.

A slightly higher incidence in older patients was observed in the analyses considering all TEAEs (category 'Total AEs') and nervous system disorders while no clear signal of an increased risk with increasing age was found for any of the other categories of TEAEs.

The  incidences  of  the  treatment  discontinuations  in  both  studies  are  balanced  across  the  different treatment groups.

##  ADRs proposed for inclusion in the PI

Based  on  the  safety  data  submitted,  the  following  additional  ADRs  are  proposed  for  inclusion  in  the TRYDONIS  /  RIARIFY  SmPC:  pharyngeal  erythema,  pharyngeal  inflammation  and  dry  throat  (SOC: Respiratory, Thoracic and Mediastinal Disorders), (aphthous) stomatitis (SOC: Gastrointestinal Disorders). In  addition,  changes  in  frequency  are  proposed  for  the  following  existing  ADRs  in  the  TRYDONIS  / RIARIFY SmPCX, based on the frequency reported in studies TRIPLE 5, TRIPLE 6, TRIPLE 7 and TRIPLE 8: hypertension from 'rare' to 'uncommon'; dysuria and urinary retention from 'uncommon' to 'rare' and asthenia from 'uncommon' to 'rare', respectively. This is acceptable and supported by the safety data provided in the application.

Additionally in section 4.4 of the SmPC, a paragraph on the risk of visual disturbance is added following beclometasone PSUSA/00000306/201612 procedure and the PRAC recommendation dated July 2018. The ADR table in section 4.8 is updated accordingly.

## 2.5.2.  Conclusions on clinical safety

The safety profile of TRYDONIS / RIARIFY in study TRIPLE 8 was in line with the pharmacologic class of each component and with the dual combination IND/GB. The known risk of pneumonia with ICScontaining products in COPD patients has to be taken into account when balancing the benefit against the risk.

## 2.5.3.  PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6.  Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 6.0 is acceptable. The PRAC endorsed PRAC Rapporteur assessment report is attached.

The MAH is reminded that, within 30 calendar days of the receipt of the Opinion, an updated version of Annex I of the RMP template, reflecting the final RMP agreed at the time of the Opinion should be submitted to h-eurmp-evinterface@emea.europa.eu.

The CHMP endorsed the Risk Management Plan version 6.0 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

| Important identified risks   | /                                    |
|------------------------------|--------------------------------------|
| Important potential risks    | - Cardio- and cerebrovascular events |
| Missing information          | /                                    |

The list of safety concerns was updated to be in line with GVP Module V, revision 2 and focuses now on the risks that are likely to have an impact on the risk-benefit balance of the product.

## Pharmacovigilance plan

| Study (Study short name, and title)                                                                                                                                                                                        | Summary of objectives                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                                  | Milestones (Required by regulators)                                                                                                                                                                                        | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Status (planned/on-going)                                                                                                                                                                                                  |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 1 - Imposed mandatory additional Pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional Pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional Pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional Pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional Pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 2 - Imposed mandatory additional Pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional Pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional Pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional Pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional Pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 3 - Required additional Pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional Pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional Pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional Pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional Pharmacovigilance activities                                                                                                                                                              |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |

Having considered the data submitted, the CHMP agrees that Routine pharmacovigilance is sufficient to identify and characterise the risks of the product. The CHMP also considered that Routine PhV remains sufficient to monitor the effectiveness of the risk minimisation measures.

## Risk minimisation measures

| Safety concern                     | Routine risk minimisation measures                                                                                    | Pharmacovigilance activities                                                                                                        |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| Cardio- and cerebrovascular events | -Statement in section 4.4 and labelled in section 4.8 of the SmPC -Statement in section 2 and in section 4 of the PL. | Routine PhV activities also includes the monitoring of the results of the PASS on cardio- and cerebrovascular outcomes (EUPAS5035). |

The CHMP, having considered the data submitted, was of the opinion that the proposed routine risk minimisation measures are sufficient to minimise the risks of the product in the proposed indications.

<div style=\"page-break-after: always\"></div>

## 2.7.  Update of the Product information

As a consequence of this new indication, sections 4.1, 4.8 and 5.1 of the SmPC have been updated. In addition, a new warning with regard to the risk of visual disturbance associated with beclametasone has been added to the product information. The Package Leaflet has been updated accordingly.

In addition, the list of local representatives in the PL has been revised to amend contact details for the representative of Ireland.

## 2.7.1.  User consultation

A justification for not performing a user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons: the changes are minimal and would not affect the results of the original user consultation.

## 3.  Benefit-Risk Balance

## 3.1.  Therapeutic Context

## 3.1.1.  Disease or condition

TRYDONIS / RIARIFY is  a  triple  combination  of  an  ICS,  LABA  and  LAMA.  The  product  is  a  fixed  dose combination  of  BDP,  FF  and  GB  and  formulated  as  a  HFA  solution  to  be  delivered  via  a  pMDI  with  a nominal dose per actuation of BDP, FF and GB of 100 µg, 6 µg and 12.5 µg, respectively.

The approved indication is:

'Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).'

COPD  is  a  progressive  disease  characterised  by  increasing  obstruction  to  airflow  and  the  progressive development of respiratory symptoms including chronic cough, increased sputum production, dyspnoea and wheezing. The objective of pharmacological treatment of is to prevent and control symptoms, reduce the frequency and severity of exacerbations, and improve general health status and exercise tolerance.

Smoking cessation (including passive smoking) is extremely important. Ideally treatment of COPD would slow its progression but this has never been convincingly demonstrated. Long term domiciliary oxygen has been shown to prolong life but confines the patient to home for protracted periods. In recent years there has been increasing emphasis on physical training and rehabilitation. Moderate and severe COPD exacerbations are generally treated with antibiotics and oral corticosteroids. Maintenance treatment is by combinations of oral and inhaled bronchodilators and anti-inflammatory agents.

## 3.1.2.  Available therapies and unmet medical need

Despite the availability of a multiplicity of pharmacological treatments none of them modifies the progress of the disease and none can be considered to have a really major benefit on its most common symptoms of cough, breathlessness, excess sputum production, and thoracic discomfort due to hyperinflation.

ICS/LABA  combination  products  are  considered  key  to  the  symptomatic  management  of  COPD.  The combination has been shown to improve lung function, health status, and to reduce COPD exacerbations compared with either agent alone. LAMAs have been shown to improve lung function, relieve symptoms, increase exercise capacity, improve quality of life, and reduce COPD exacerbations to a greater extent

<div style=\"page-break-after: always\"></div>

than short-acting bronchodilators. As disease severity increases, COPD treatment guidelines recommend an incremental approach to pharmacological treatment, involving the use of combinations of drug classes with different or complementary mechanisms of action (GOLD 2018).

## 3.1.3.  Main clinical studies

The main phase 3 clinical study supporting this extension of indication is one pivotal study (study TRIPLE 8). In this randomised, double-blind, double-dummy, 2-arm parallel group study involving 1532 patients with COPD, the fixed combination of BDP/FF/GB were compared with the dual combination IND/GB over 52 weeks. The primary outcome was the rate of moderate-to-severe COPD exacerbations over 52 weeks of treatment.

The inclusion and exclusion criteria for Study TRIPLE 8 were consistent with those from Study TRIPLE 5 and study TRIPLE 6 which were pivotal for the initial MAA.

## 3.2.  Favourable effects

The  currently  approved  indication  wording  '…[COPD  patients]  who  are  not  adequately  treated  by  a combination of an inhaled corticosteroid and a long-acting β2-agonist' highlights the lack of evidence to claim a step-up indication from the combination of a long-acting muscarinic receptor antagonist (LAMA) and a long-acting beta2 agonist (LABA) due to the absence of the combination of LAMA and LABA as comparator (e.g. IND/GB) in the pivotal Phase III study at time of the MAA of TRYDONIS / RIARIFY, a triple combination of an inhaled corticosteroid (ICS), and LABA and LAMA.

In study TRIPLE 8 the MAH demonstrates advantages for the fixed combination of BDP/FF/GB over the dual therapy IND/GB in symptomatic COPD patients with a risk of exacerbation. In the ITT population, the rate of moderate-to-severe COPD exacerbations over 52 weeks of treatment was significantly lower with BDP/FF/GB  than  with  IND/GB,  with  a  rate  ratio  of  0.848  (95%  CI  [0.723,  0.995],  p-value=0.043) indicating  a  15%  reduction  in  the  exacerbation  rate.  Overall,  the  applicant  has  demonstrated  the superiority of the triple combination over the dual components.

## 3.3.  Uncertainties and limitations about favourable effects

Notable, the p-value of the primary analysis of the primary endpoint (ITT dataset) are slightly less than the  conventional  0.05  significance  level  (p=0.043).  The  upper  limit  of  the  95%  CI  for  the  adjusted exacerbation rate ratio was 0.995. Results of the PP population confirmed the estimated effect size, but barely missed statistical significance (p=0.050, upper limit of 95% CI=1.000).

The consistency of statistical significance is not guaranteed over a broad range of primary analyses and sensitivity  analyses.  The  following  analyses  do  not  or  did  not  yield  a  significant  result  at  a  p-level  of &lt;0.05:

- time to first moderate or severe COPD exacerbation (p=0.219);
- FEV1 responder analysis (change from baseline to week 52 ≥100 mL; p=0.198);
- missing data imputation for COPD exacerbation rate (CR, J2R);
- use of other time gaps in order to decide whether two (or more) episodes represent a single (or new) exacerbation episode (15 or 20 days);
- SGRQ responder analysis (change from baseline to week 52 ≤ -4 units; p=0.068).

The  difference  in  moderate-to-severe  COPD  exacerbations  over  52  weeks,  in  absolute  terms  (an estimated reduction in 0.09 exacerbations per patient per year, from 0.594 with LABA/LAMA to 0.504

<div style=\"page-break-after: always\"></div>

with  the  triple  therapy),  is  considered  modest  from  a  clinical  perspective.  Nevertheless,  it  is  conceded that the chosen study design and population - in contrast to other recently published studies - did not penalise  the  comparator  group  nor  did  it  inflate  artificially  the  rate  of  moderate  and  severe  COPD exacerbations.

Doubts  have  emerged  regarding  the  internal  validity  and  data  quality  of  the  study.  As  is  only  now apparent from the requested documentation which was not submitted with the initial application (i.e. the so-called Data Review Report),  the secondary population for analysis (i.e. the per-protocol population) modified after unblinding. Though these post hoc modifications applied to the PP population appear to have had no impact on the analysis of the primary response variable, they raise doubts as to the quality of reported data and the understanding of the applicant for GCP requirements and disclosure obligations of an applicant in the context of a marketing authorisation procedure.

In addition, the MAH has undertaken limited efforts to assess and assure the reliability and integrity of the trial systems against own written standards and applicable laws and regulations. Annual audit plans / programmes were finalised with significant delay and for the pivotal study TRIPLE 8, only a single site audit was performed that followed a proactive and risk-based approach. This finding may also challenge the internal validity of the study / data reliability.

## 3.4.  Unfavourable effects

The safety profile of TRYDONIS / RIARIFY in study TRIPLE 8 was in line with the pharmacologic class of each component and also with the comparator IND/GB. The following additional ADRs are proposed for inclusion  in  the  TRYDONIS  /  RIARIFY  label:  pharyngeal  erythema,  pharyngeal  inflammation  and  dry throat (SOC: Respiratory, Thoracic and Mediastinal Disorders), (aphthous) stomatitis (SOC: Gastrointestinal  Disorders).  In  addition,  changes  in  frequency  are  proposed  for  the  following  existing ADRs in the TRYDONIS / RIARIFY label, based on the frequency reported in studies TRIPLE 5, TRIPLE 6, TRIPLE 7 and TRIPLE 8: hypertension from 'rare' to 'uncommon'; dysuria and urinary retention from 'uncommon' to 'rare' and asthenia from 'uncommon' to 'rare', respectively.

Overall, the AE profile of TRYDONIS / RIARIFY is well understood; none of the active substances is a new active substance and all have been used over periods of at least years individually and in combination in treating COPD patients of various grades of severity. To date, 3106 patients have been treated with the triple combination (counting the free and fixed combinations) many of them for 52 weeks. There are no evident new safety signals and the treatment associated unwanted effects are of a frequency and nature to be expected given the nature of the clinical development.

## 3.5.  Uncertainties and limitations about unfavourable effects

Pneumonia  data  collected  for  TRYDONIS  /  RIARIFY  in  study  TRIPLE  8  and  previous  trials  are  not suggestive of a relevantly increased risk of pneumonia when BDP is added to a LABA LAMA combination. In study TRIPLE 8, the pneumonia event rate per 1'000 subject-years under triple therapy (44.6) was slightly  higher  than  those  observed  in  the  pivotal  trials  endorsing  the  initial  marketing  authorisation (TRIPLE 5: 38.9; TRIPLE 6: 29.2). However, no firm conclusions can be drawn in that respect given the limited nature of the data. Due to the low observed event rate, study TRIPLE 8 (32 pneumonia events) and the pooled analysis integrating data from studies TRIPLE 5 to TRIPLE 8 (100 pneumonia events) only had low statistical power to generate a robust estimate of the true risk of pneumonia. Moreover, data and analyses  presented  are  not  sufficient  to  establish  whether  the  risk  of  pneumonia  of  an  ICS-containing regimen  varies  with  the  corticosteroid  moiety  and/or  the  formulation  itself.  Latest  scientific  data generated in 2015 in the framework of the referral triggered by the European Commission confirmed the risk  of  pneumonia  with  these  combination  products,  but  did  not  find  any  conclusive  evidence  of differences in this risk for different products. Differences in study design, methodology for confirming the

<div style=\"page-break-after: always\"></div>

diagnosis  of  pneumonia,  sample  size  and  populations  assessed  also  do  not  allow  drawing  meaningful conclusions of whether TRYDONIS / RIARIFY has a more favourable benefit-risk profile in that respect than the triple combination assessed in the IMPACT study.

## 3.6.  Effects Table

Table 23: Effects Table for [TRYDONIS / RIARIFY, COPD]

| Effect                           | Short description                                                                                      | Unit                      | BDP/FF/G B           | IND/G B              | Uncertainties / Strength of evidence                                                                                 | References           |
|----------------------------------|--------------------------------------------------------------------------------------------------------|---------------------------|----------------------|----------------------|----------------------------------------------------------------------------------------------------------------------|----------------------|
| Favourable Effects               | Favourable Effects                                                                                     | Favourable Effects        | Favourable Effects   | Favourable Effects   | Favourable Effects                                                                                                   | Favourable Effects   |
| COPD exacerb ation rate          | rate of moderate-to- severe COPD exacerbations over 52 weeks                                           |                           | 0.504                | 0.594                | Rate ratio (95% CI, p- value) 0.848 (0.723, 0.995, 0.043)                                                            | TRIPLE 8             |
| Unfavourable Effects             | Unfavourable Effects                                                                                   | Unfavourable Effects      | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                                                 | Unfavourable Effects |
| Pneumo nia                       |                                                                                                        | Event rate per 1000 subje | 44.6                 | 41.0                 | ICS-containing treatments are known to increase the risk of pneumonia in COPD patients.                              | TRIPLE 8             |
| MACE                             |                                                                                                        | cts                       | 25.1                 | 59.4                 | Results may be biased due to the non- adjudication of MACEs for TRIPLE 8 study, see also Annex 1 Q23                 | TRIPLE 8             |
| Class effects of ICS/LA MA/LAB A | Muscle spasms, dry mouth, oral candidiasis, dysphonia, headache, oropharyngeal pain, sinus tachycardia |                           |                      |                      | Treatment adverse events were of similar natures. No particular pattern or concern emerges with respect to BDP/FF/GB | TRIPLE 8             |

Abbreviations: See list of Abbreviations

## 3.7.  Benefit-risk assessment and discussion

## 3.7.1.  Importance of favourable and unfavourable effects

For  patients  at  risk  of  COPD  exacerbations,  the  Global  Initiative  for  Chronic  Obstructive  Lung  Disease (GOLD)  strategy  document  for  the  management  of  patients  with  COPD  recommends  an  incremental approach to therapy, beginning with either a LAMA, LAMA/LABA, or ICS/LABA therapy [GOLD, 2018]. If patients  develop  further  exacerbations,  escalation  of  pharmacologic  therapy  is  recommended.  For example, patients on LAMA therapy can be switched to a LAMA/LABA or ICS/LABA with further escalation to triple ICS/LAMA/LABA therapy or those on a dual therapy can be switched to triple therapy if required.

In  other  words,  triple  therapy  is  currently  thought  to  be  best  used  as  an  escalation  therapy  for  those incompletely controlled with dual therapy, either ICS/LABA or LABA/LAMA (GOLD 2018). The applicant has  demonstrated  the  superiority  (although  marginal  statistically  significant)  of  the  triple  combination over LAMA/LABA combination.

From a safety point of view, the provided data on pneumonia are not suggestive of a relevantly increased risk of pneumonia when an ICS is added to double bronchodilator therapy. In contrast to other studies comparing ICS/LABA/LAMA (e.g. Lipson DA at al. 2018), no higher risk was observed when adding an ICS to double bronchodilator therapy. However, the interpretation of these observations is somehow difficult,

<div style=\"page-break-after: always\"></div>

but most likely the sample size/statistical power of TRIPLE 8 was not large enough to detect a difference among groups, even if one may have been present.

## 3.7.2.  Balance of benefits and risks

Although the effect on exacerbation rate is marginal statistically significant and modest from a clinical perspective,  the  applicant  has  sufficiently  shown  that  the  decrease  in  exacerbations  demonstrated  is sufficient to offset the well-known rate of pneumonia in patients taking an ICS containing triple therapy compared to patients on dual LABA/LAMA therapy in patients with moderate to severe COPD.

## 3.7.3.  Additional considerations on the benefit-risk balance

N/A

## 3.8.  Conclusions

The overall B/R of TRYDONIS / RIARIFY in the extended indication is positive.

## 4.  Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication, based on results from two Phase III studies: Triple 7 (CCD-05993AA1-07) and Triple 8 (CCD-05993AA1-08), to include maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by combination of a longacting beta2-agonist and a long-acting muscarinic antagonist. Sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated accordingly to reflect the studies' results and add a new warning with regards to the risk of visual disturbance associated with beclometasone following the PSUSA recommendation PSUSA/00000306/201612. The package leaflet and the risk management plan (version 6.0) are updated accordingly.

In addition, the Worksharing  applicant  (WSA)  took  the  opportunity  to  update  the  list  of  local representatives in the Package Leaflet.

The worksharing procedure leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product in

<div style=\"page-break-after: always\"></div>

accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## 5.  EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of indication, based on results from two Phase III studies: Triple 7 (CCD-05993AA1-07) and Triple 8 (CCD-05993AA1-08), to include maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by combination of a longacting beta2-agonist and a long-acting muscarinic antagonist. Sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated accordingly to reflect the studies' results and add a new warning with regards to the risk of visual disturbance associated with beclometasone following the PSUSA recommendation PSUSA/00000306/201612. The package leaflet and the risk management plan (version 6.0) are updated accordingly.

## Summary

Please refer to the scientific discussion Riarify EMEA/H/C/004836/WS1554/0002 and Trydonis EMEA/H/C/004702/WS1554/0002.

## Attachments

1. SmPC, Annex II, Package Leaflet as adopted by the CHMP on 28 February 2019.

<div style=\"page-break-after: always\"></div>

## Reminders to the MAH

1. In accordance with Article 13(3) of Regulation (EC) No 726/2004 the Agency makes available a European Public Assessment Report (EPAR) on the medicinal product assessed by the Committee for Medicinal Products for Human Use. The EPAR is first published after the granting of the initial marketing authorisation (MA) and is continuously updated during the lifecycle of the medicinal product. In particular, following a major change to the MA, the Agency further publishes the assessment report of the CHMP and the reasons for its opinion in favour of granting the change to the authorisation, after deletion of any information of a commercially confidential nature.

Should you consider that the CHMP assessment report contains commercially confidential information, please provide the EMA Procedure Assistant your proposal for deletion of commercially confidential information (CCI) in 'track changes' and with detailed justification by 15 March 2019. The principles to be applied for the deletion of CCI are published on the EMA website at https://www.ema.europa.eu/documents/regulatory-procedural-guideline/principles-beapplied-deletion-commercially-confidential-information-disclosure-emea-documents\\_en.pdf.

2. The MAH is reminded that, within 30 calendar days of the receipt of the Opinion, an updated version of Annex I of the RMP template, reflecting the final RMP agreed at the time of the Opinion should be submitted to h-eurmp-evinterface@emea.europa.eu.
3. If the approved RMP is using Rev. 2 of the 'Guidance on the format of the RMP in the EU' and the RMP 'Part VI: Summary of the risk management plan' has been updated in the procedure, the MAH is reminded to provide to the EMA Procedure Assistant by Eudralink a PDF version of the 'Part VI: Summary of the risk management plan' as a standalone document, within 14 calendar days of the receipt of the CHMP Opinion. The PDF should contain only text and tables and be free of metadata, headers and footers.
4. The MAH is reminded to submit an eCTD closing sequence with the final documents provided by Eudralink during the procedure (including final PI translations, if applicable) within 15 days after the Commission Decision, or prior to the next regulatory activity, whichever is first. For additional guidance see chapter 4.1 of the Harmonised Technical Guidance for eCTD Submissions in the EU .